

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## A Cohort Study of the Characteristics and Outcomes in Patients with COVID-19 and In-Hospital Cardiac Arrest

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-054943
Article Type:	Original research
Date Submitted by the Author:	06-Jul-2021
Complete List of Authors:	<p>Holm, Astrid; University of Gothenburg, Department of Molecular and Clinical Medicine            Jerkeman, Matilda; University of Gothenburg, Department of Molecular and Clinical Medicine            Sultanian, Pedram; University of Gothenburg, Department of Molecular and Clinical Medicine            Lundgren, Peter; University of Gothenburg, Department of Molecular and Clinical Medicine; Kalmar County Hospital, Department of Internal Medicine            Ravn-Fischer, Annica; University of Gothenburg, Department of Molecular and Clinical Medicine            Israelsson, Johan; Kalmar County Hospital, Department of Internal Medicine; Linnaeus University, Faculty of Health and Life Sciences            Giesecke, Jasna; Danderyd University Hospital            Herlitz, Johan; University of Borås, Centre for Prehospital Research            Rawshani, Araz; University of Gothenburg, Department of Molecular and Clinical Medicine</p>
Keywords:	COVID-19, CARDIOLOGY, Adult cardiology < CARDIOLOGY, Coronary heart disease < CARDIOLOGY

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

# A Cohort Study of the Characteristics and Outcomes in Patients with COVID-19 and In-Hospital Cardiac Arrest

Astrid Holm, MD<sup>1</sup>, Matilda Jerkeman, MD<sup>1</sup>, Pedram Sultanian, MD<sup>1</sup>, Peter Lundgren, MD, PhD<sup>1,3,7</sup>, Annica Ravn-Fischer, MD, PhD, Docent<sup>1</sup>, Johan Israelsson, PhD<sup>3,4</sup>, Jasna Giesecke, RN<sup>5</sup>, Johan Herlitz, MD, PhD<sup>2,6</sup>, Araz Rawshani, MD, PhD<sup>1,2</sup>

## Affiliations:

<sup>1</sup>Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden

<sup>2</sup>The Swedish Registry for Cardiopulmonary Resuscitation, Centre of Registries, Västra Götaland County, Sweden

<sup>3</sup>Department of Internal Medicine, Division of Cardiology, Kalmar County Hospital, Region Kalmar County, Sweden

<sup>4</sup>Faculty of Health and Life Sciences, Linnaeus University, Kalmar, Sweden

<sup>5</sup>RN, Lead CPR coordinator, Clinicum- Centre for clinical skills, interprofessional education and advanced medical simulation, Danderyd University Hospital, Stockholm, Sweden

<sup>6</sup>Prehospen – Centre for Prehospital Research, University of Borås, Borås, Sweden

<sup>7</sup>Region Västra Götaland, Sahlgrenska University Hospital, Department of Cardiology, Gothenburg, Sweden

## Contact information:

Astrid Holm

Email: [astrid.holm@gu.se](mailto:astrid.holm@gu.se)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 Phone: +358 400707722

2

3

4 **Manuscript word count:** 3592

5

6 **Keywords:** COVID19, SARS-COV-2, Coronavirus, cardiac arrest, in-hospital cardiac arrest

7

## 1 Key Points

2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

2 **Question:** What are the Characteristics, causes and outcomes in patients with COVID-19 who  
3 suffer an in-hospital cardiac arrest (IHCA)?

4 **Findings:** In the registry-based observational study we found that during pandemic peaks, up  
5 to one fourth of all IHCAs are complicated by COVID-19, and these patients have halved  
6 chance of survival.

7 **Meaning:** The survival rate of patients with COVID-19 associated IHCA is low with women  
8 displaying the worst outcomes.

## 9 Abstract

10 **Objective:** We studied characteristics, survival, causes of cardiac arrest, conditions preceding  
11 cardiac arrest, predictors of survival, and trends in the prevalence of COVID-19 among IHCA  
12 cases. Data on characteristics and outcomes in patients with COVID-19 who suffer an in-  
13 hospital cardiac arrest (IHCA) is scarce.

14 **Design and setting:** Registry-based observational study.

15 **Participants:** We studied all cases of IHCA receiving CPR ( $\geq 18$  years of age) in the Swedish  
16 Registry for Cardiopulmonary Resuscitation from 15/03/2020 to 31/12/2020. A total of 1613

1 patients were included and divided into the following groups: ongoing infection (**COVID+**;  
2 n=182), no infection (**COVID-**; n=1062) and unknown/not assessed (**UNA**; n=369).

3 **Main outcomes and measures:** We studied monthly trends in proportions of COVID-19  
4 associated IHCAs, causes of IHCA in relation to COVID-19 status, clinical conditions  
5 preceding the cardiac arrest and predictors of survival.

6 **Results:** The rate of COVID+ patients suffering an IHCA increased to 23% during the first  
7 pandemic wave (April), then abated to 3% in July, and then increased to 19% during the  
8 second wave (December). Among COVID+ cases, 43% had respiratory insufficiency or  
9 infection as the underlying cause of the cardiac arrest, compared to 18% among COVID-  
10 cases. The most common clinical sign preceding cardiac arrest was hypoxia (57%) among  
11 COVID+ cases. Odds ratio for 30-day survival for COVID+ cases was 0.50 (95% CI 0.33-  
12 0.76) compared with COVID- cases. At the end of follow-up, 19% of COVID+ cases and  
13 35.6% of COVID- cases had been discharged alive. Among COVID+ cases, 22% of men,  
14 compared with 14% of women, were discharged alive.

15 **Conclusion:** During pandemic peaks, up to one fourth of all IHCAs are complicated by  
16 COVID-19, and these patients have halved chance of survival, with women displaying the  
17 worst outcomes.

## 1 Article Summary

### 2 Strengths and limitations of this study

- 3 • A major strength of our study is that it includes all IHCA in Sweden which were  
4 reported to the Swedish Registry for Cardiopulmonary Resuscitation.
- 5 • The sample recorded in the Swedish Registry for Cardiopulmonary Resuscitation is  
6 unbiased since all hospitals participate in the registry and all hospitals report data on  
7 COVID-19 status
- 8 • A limitation is that we do not know the severity of the COVID-19 infection, and we  
9 do not know if COVID-19 was the main reason for admission to hospital.
- 10 • Our study only includes IHCA receiving CPR which leaves out all other patients with  
11 IHCA, e.g with a Do Not Attempt Resuscitation order.
- 12 • It is important to stress the fact that our regression model that included only COVID-  
13 19 cases must be interpreted with caution due to the large number of predictors in the  
14 model, which had relatively few patients.



## 1 Introduction

2 The COVID-19 pandemic has, as of May 1<sup>st</sup> 2021 infected over 159,000,000 persons and lead  
3 to the demise of over 3,321,000 individuals(1).The Swedish Public Health Authority declared  
4 on March 16<sup>th</sup> 2020 that community spread of COVID-19 had commenced, and COVID-19 is  
5 now the third leading cause of death in Sweden(2, 3).

6 A recent study including over 5,000 critically ill patients with COVID-19 showed that in-  
7 hospital cardiac arrest (IHCA) is common and associated with poor survival(4). An early  
8 study from Wuhan also showed poor survival after IHCA among COVID-19 patients(5). We  
9 recently studied IHCA in the Swedish Registry for Cardiopulmonary Resuscitation (SRCR)  
10 and showed a 2.3-fold increase in 30-day mortality among cases with COVID-19 compared to  
11 pre-pandemic cases and this was mainly driven by a 9-fold increase in mortality among  
12 women with COVID-19. During the study period no case of IHCA with COVID-19 was  
13 discharged alive from the hospital(6).

14 The current study expands our previous investigation, including more patients, longer follow-  
15 up and emphasizes the causes of cardiac arrest in COVID-19, predictors of survival,  
16 coexisting conditions, and trends in the prevalence of COVID-19 among IHCA cases.

## 1 **Methods**

### 2 **Data sources**

3 The study is a registry-based observational study with data obtained from the SRCR during  
4 the time period 15/03/2020 to 31/12/2020.

5 The SRCR is a national quality registry and has included IHCA cases since 2005. The data is  
6 collected by trained nurses who report patient data using a web-based protocol. The registry  
7 has previously been described in detail(7). Vital status was obtained from the Swedish  
8 Population Registry and the last day of follow up was 31/12/2020.

### 9 **Study population**

10 The study population included all patients  $\geq 18$  years of age suffering from IHCA and  
11 receiving CPR throughout Sweden during the period 15/03/2020 to 31/12/2020. We used 15th  
12 of March as the start date of the pandemic as the Swedish Public Health Authority declared on  
13 March 16<sup>th</sup> 2020 that COVID-19 was community spread in Sweden(3). On 1<sup>st</sup> of April the  
14 SRCR started collecting data about COVID-19 status, and retrospectively identified 60  
15 patients with COVID-19 who suffered IHCA during March (they were included in the study).  
16 Patients were divided into the following three groups: ongoing infection (COVID+; n=182),  
17 no infection (COVID-; n=1062) and unknown/not assessed (UNA; n=369). COVID+ was

1  
2  
3  
4 1 defined as patients registered with an ongoing COVID-19 infection, suspected ongoing  
5  
6  
7 2 infection or patients with a recent infection(n=29).  
8  
9

### 10 3 **Variable definitions**

11  
12  
13  
14 4 In SRCR a patient with cardiac arrest was defined as an unconscious patient with no or  
15  
16  
17 5 abnormal breathing, in whom resuscitation or defibrillation was attempted. IHCA was defined  
18  
19  
20 6 as cardiac arrest in patients admitted to the hospital.  
21  
22

23  
24 7 With regards to previous coexisting conditions heart failure was defined as any heart failure  
25  
26  
27 8 described before cardiac arrest. Kidney failure was defined as estimated glomerular filtration  
28  
29  
30 9 rate (eGFR) below 60 ml/min/1.73 m<sup>2</sup>, calculated using the highest creatinine before cardiac  
31  
32  
33  
34 10 arrest with Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula based  
35  
36  
37 11 on sex, age and creatinine. The SRCR records data on the highest creatinine levels analyzed  
38  
39  
40  
41 12 up to six months prior to CA. Diabetes was defined as any diabetes diagnosis, regardless of  
42  
43  
44 13 type. Cancer was defined as any previously known cancer. Acute myocardial infarction (MI)  
45  
46  
47 14 was defined as an MI within 72 hours of CA. Previous myocardial infarction was defined as  
48  
49  
50  
51 15 MI occurring earlier than 72 hours preceding the CA.  
52  
53

54 16 Regarding clinical conditions one hour prior to CA, arrhythmia was defined as any  
55  
56  
57  
58 17 arrhythmia, hypoxia was defined as an oxygen saturation below 90%, hypotension was  
59  
60

1 defined as systolic blood pressure below 90 mmHg, seizure was defined as any seizure with  
2 loss of consciousness, and heart failure was defined as any heart failure with pulmonary  
3 edema or severe shortness of breath with rales.

4 A monitored ward was defined as a coronary care unit(CCU), an intensive care unit(ICU), an  
5 operational room(OR), an emergency room(ER), an intermediate care unit(IMCU) or a  
6 catheterization laboratory(Cath lab). A non-monitored ward was defined as a regular ward  
7 (RW). All other wards were defined as other ward, e.g. outpatient lab, radiology department,  
8 etc.

## 9 **Statistical analyses**

10 Patient characteristics are reported in means and medians, along with standard deviations and  
11 interquartile ranges, respectively. The Kaplan-Meier estimator was used for defining survival  
12 distributions; the log rank test was used to test for differences in survival.

13 Logistic regression was used to calculate odds ratios for 30-days survival. These models  
14 assessed the association between COVID-19 status and 30-days survival, while adjusting for  
15 age, sex and initial rhythm (shockable or non-shockable). Subgroup analyzes were done for  
16 men, women, age  $\geq 70$  years, age  $< 70$  years, heart failure, kidney failure, diabetes, myocardial  
17 infarction and cancer.

1  
2  
3  
4 1 In order to obtain estimates of overall survival, we used Cox proportional hazards model with  
5  
6  
7 2 hours since CA as the time scale. The proportional hazards assumption was fulfilled for all  
8  
9  
10 3 variables.

11  
12  
13  
14 4 We used the MICE (Multiple Imputation By Chained Equations) algorithm to impute missing  
15  
16  
17 5 values(8, 9) (Supplementary Figure 1). The imputed data set was used to calculate odds ratios  
18  
19  
20  
21 6 for 30-days survival in the overall group, as well as in COVID+ and COVID- cases. These  
22  
23  
24 7 models included age, sex, initial rhythm, time to start of cardiopulmonary resuscitation  
25  
26  
27 8 (CPR), time of CA, previous MI, location (other ward vs monitored, and non-monitored ward  
28  
29  
30  
31 9 vs monitored), heart failure, EKG monitoring, diabetes and acute MI.

32  
33  
34  
35 10 Analyses were done in R (v. 4.0.3, R Foundation for Statistical Computing) using RStudio.

36  
37  
38  
39 11 The study was approved by the Swedish Ethical Review Authority (ID 2020-02017).

## 40 41 42 43 12 **Patient and Public Involvement statement:**

44  
45 13 No patients were involved.

## 46 47 48 49 50 51 14 **Results**

52  
53 15 A total of 2,227 patients were enrolled in the SRCR between 01/01/2020 and 31/12/2020.

54  
55  
56  
57 16 After excluding patients <18 years (n=68) and pre-pandemic cases (n=546), 1,613 cases

58  
59  
60 17 remained from 15/03/2020 to 31/12/2020 and constituted the final study population

1 (Supplementary Figure 2). There was a high rate of information on COVID-19 status during  
2 the study period among patients registered in the registry (Supplementary Figure 3).

### 3 **Baseline characteristics**

4 The overall mean age was 70.8 years, and the proportion of women was 37.6%. At the end of  
5 follow-up, 341 (32.7%) patients were alive. The mean age was similar in the three groups:  
6 70.9 years among COVID+, 71.0 years among COVID– cases, and 70.2 years in cases with  
7 UNA (Supplementary Figure 4). The proportion of women was also similar; 37.6% in  
8 COVID+, 36.6% in COVID– and 41.0% in UNA cases.

9 A regular ward (RW) was the most common place of cardiac arrest in all 3 groups with rates  
10 of 45.1% among COVID+, 44.1% among COVID– and 31.4% among UNA (Table 1). The  
11 emergency room (ER) was the second most common location for COVID+ cases (15.9%).  
12 The ER was the location of cardiac arrest in 17.6% of UNA cases and 13.1% for COVID–  
13 cases.

14 Regarding comorbidities, acute myocardial infarction was observed in 12.0% of COVID+ and  
15 23.6% of COVID– cases. Previous myocardial infarction was observed in 11.7% of COVID+,  
16 20.8% of COVID– and 11.7% of UNA cases. The prevalence of heart failure, cancer and  
17 diabetes was similar across all groups (Table 1).

1 Fewer cases among COVID+ individuals had a shockable rhythm (17.3%), compared with  
2 COVID- (24.9%) and UNA (27.0%). Likewise, fewer cases among COVID+ (22.7%) were  
3 defibrillated, compared with COVID- (31.5%) and UNA (32.8%). COVID+ cases were  
4 ventilated in 54.8% of cases before rescue team arrival, as compared with 63.2% and 69.2%  
5 in COVID- and UNA, respectively.

### 6 **Follow-up and crude survival**

7 Return of spontaneous circulation (ROSC) after initial resuscitation, was less common in  
8 COVID+ cases, as compared with COVID- and UNA. Also, angiography, PCI, pacemaker  
9 and ICD implantation post cardiac arrest were less common in COVID+ cases.  
10 Survival at 30-days was 37.3% in COVID- patients, compared to 22.5% among COVID+  
11 patients (Table 1), and 35.6% of COVID- patients were discharged alive, compared with  
12 19.0% of COVID+ patients.

### 14 **Sex specific characteristics**

15 Acute myocardial infarction was observed in 21.2% of COVID+ women and 7.6% of  
16 COVID+ men. Previous myocardial infarction was observed in 4.7% of COVID+ women and  
17 16.2% of COVID+ men. The prevalence of previous stroke, renal failure, heart failure, cancer

1 and diabetes were similar among men and women, as was location at the time of cardiac  
2 arrest. COVID+ men were more likely to have a shockable rhythm (20.8%) compared with  
3 COVID+ women (11.5%) and to be defibrillated (26.4% in men vs 16.9% in women). In all,  
4 22.2% of COVID+ men were discharged alive from hospital compared to 14.0% of COVID+  
5 women (Supplementary Table 1).

### 6 **Monthly trends in COVID-19 associated IHCA**

7 In March, April and May 14%, 23% and 20% of patients suffering IHCA were COVID+ (data  
8 from 16<sup>th</sup> March). The proportion of COVID+ cases diminished rapidly during June to July.  
9 From September onwards the COVID+ cases increased again to reach 19% in December. In  
10 Figure 1A additional details regarding monthly variations are presented.



## 1 Etiology of IHCA

2 The most common cause of IHCA among COVID+ was respiratory insufficiency (24%,  
3 n=24). The second most common cause was sepsis or other infection (19%, n=19) among  
4 COVID+. Respiratory insufficiency and sepsis/other infection were less common in the other  
5 groups (Figure 1B), which instead displayed higher rates of acute myocardial infarction.

## 6 Clinical conditions one hour prior to IHCA

7 As evident in Figure 1C which describes the clinical conditions preceding (up to 60 minutes)  
8 the cardiac arrest, hypoxia was more common among COVID+ (57%), as compared with  
9 COVID- (34%). Regarding arrhythmia, heart failure, hypotension and seizure the percentages  
10 were more similar.

## 11 Survival analysis

12 The Kaplan Meier plots (Figure 2) show that COVID+ cases generally had a lower  
13 probability of survival compared to COVID- and UNA cases. The overall 30-day survival  
14 (Figure 2A) was 21% among COVID+, compared with 36% in COVID- cases (p=0.00086).  
15 The subgroup analysis of women (Figure 2B) showed low survival rates in COVID+ cases  
16 (16% 30-day survival). Regarding age, 30 days survival among COVID+ aged <70 years was  
17 25% (Figure 2E), as compared with 18% of COVID+ cases aged 70 or older (Figure 2D).  
18 Patients with acute MI had a 30 days survival of 8% among COVID+ cases (Figure 2J).

1 Survival curves for the subgroups of individuals with cancer, heart failure and diabetes, did  
2 not display any clear patterns (Figure 2F-2H). All p values were >0.1.

3 Cox adjusted survival curves are presented in Supplementary Figure 5; COVID+ cases  
4 displayed the lowest probability of survival, whereas there was no material difference  
5 between COVID- and UNA cases.

### 6 **Odds ratios for 30-days survival**

7 When adjusted for age, sex and initial rhythm the odds ratio for 30-day survival, comparing  
8 COVID+ vs. COVID-, were 0.50 (0.33-0.76) overall, 0.53 (0.31-0.88) for men, and 0.44  
9 (0.20-0.88) for women. In the subgroup of patients with heart failure, myocardial infarction  
10 and cancer, we found no statistically significant associations, whereas in the subgroup of  
11 COVID+ patients with kidney failure, odds ratio for 30-days survival was 0.43 (0.16-0.99),  
12 when compared with COVID- (Figure 3).

### 13 **Predictors of survival**

14 Regarding predictors for 30-days survival among COVID+ we note that confidence intervals  
15 were generally wide. Lack of ECG monitoring and later start of CPR showed point estimates  
16 below 1.0, although non-significant. Odds ratio for patients treated in non-monitored wards

1 was 0.26 (95% CI 0.08-0.78) as compared with monitored ward(Figure 4). No coexisting  
2 condition was associated with survival among COVID+ cases.

3 Regarding COVID- cases the factors that were significantly associated with 30-days survival  
4 were shockable rhythm (OR 4.18 [95% CI 2.69–6.02]), ECG monitoring (2.67 [95% CI 1.82–  
5 3.95]), heart failure (OR 0.58 [95% CI 0.40–0.83]) and diabetes (OR 0.64 [95% CI 0.44–  
6 0.92]) were significantly associated with death(Figure 4).

## 7 Discussion

8 This study elucidates characteristics and outcomes in patients with COVID-19 who develop  
9 IHCA. To the best of our knowledge, this is the largest study on IHCA with individual level  
10 COVID-19 data. We show that most characteristics (e.g., underlying etiology, initial rhythm,  
11 conditions preceding cardiac arrest), as well as survival, differs markedly in COVID+ cases  
12 compared with COVID-, with the former group exhibiting worse characteristics and  
13 outcomes. Importantly, survival in COVID+ cases was half that of COVID- cases. As of  
14 writing this report the pandemic is still surging worldwide with hundreds of thousands of new  
15 cases every day. The results of our study are relevant for any health care system handling  
16 patients infected with COVID-19.

1  
2  
3  
4 1 Regarding location of CA, we note that the most common location for COVID-19 patients  
5  
6  
7 2 was regular wards, which are not monitored. This is unfortunate since our regression analysis  
8  
9  
10 3 showed that type of ward (monitored vs non-monitored) was significantly associated with  
11  
12  
13 4 survival, such that COVID+ cases in non-monitored wards displayed 74% lower probability  
14  
15  
16 5 of survival as compared with COVID+ cases in monitored wards. As compared with COVID-  
17  
18  
19 6 cases, cardiac arrest in the ER was more common in COVID+ cases. The often rapid  
20  
21  
22  
23 7 deterioration of cardiopulmonary function in patients with COVID-19 may be one of the  
24  
25  
26 8 explanations for this finding. Fewer COVID+ cases were located in the CCU which is an  
27  
28  
29 9 expected finding due to the fact that cardiac etiology was less common among these patients.  
30  
31  
32  
33  
34 10 There were high rates of COVID-19 associated cases in April and May and as expected the  
35  
36  
37 11 number of patients started increasing again from September onwards to reach 19% in  
38  
39  
40  
41 12 December at the end of our study. At the moment the incidence of severe COVID-19 cases in  
42  
43  
44 13 Sweden is still high.  
45  
46  
47  
48 14 In this study we note that the most common cause of cardiac arrest in COVID+ cases, as well  
49  
50  
51 15 as the most frequent clinical condition directly preceding the arrest, is respiratory. The high  
52  
53  
54 16 rate of respiratory etiology was driven by men (Supplementary Figure 6-7). A total of 57% of  
55  
56  
57  
58 17 cases displayed hypoxia before cardiac arrest. This may highlight an opportunity for  
59  
60

1  
2  
3  
4 1 improving outcomes; measures to prevent hypoxia and to correct it immediately may reduce  
5  
6  
7 2 the risk of cardiac arrest in patients with COVID-19. On the other hand, it can be argued that  
8  
9  
10 3 we cannot do that inference because we have not studied patients with and without hypoxia  
11  
12  
13 4 and followed them in terms of risk of developing cardiac arrest (all our cases had already  
14  
15  
16 5 developed cardiac arrest). However, we know that COVID-19 causes ARDS (acute  
17  
18  
19 6 respiratory distress syndrome) and hypoxia, which can induce cardiac arrest.  
20  
21  
22  
23  
24 7 The fact that COVID+ cases were ventilated (prior to arrival of the rescue team) less  
25  
26  
27 8 frequently than all other patients was expected, despite the fact that they displayed higher  
28  
29  
30 9 rates of hypoxia prior to cardiac arrest, as well as respiratory etiology. This observation is  
31  
32  
33  
34  
35 10 likely explained by the fact that Swedish guidelines were revised during March 2020 as well  
36  
37  
38  
39 11 as the guidelines from the European Resuscitation Council, with the recommendation that  
40  
41  
42 12 mouth-to-mouth ventilation and pocket mask ventilation should be avoided in case with  
43  
44  
45 13 confirmed or suspected COVID-19(10). Whether or not this resulted in worse outcomes for  
46  
47  
48  
49 14 COVID- 19 cases remain unsolved.  
50  
51  
52  
53 15 However, the fact that 43% of cases with COVID-19 did not have hypoxia prior to cardiac  
54  
55  
56 16 arrest suggests that other factors are important as well. Thromboembolism, myocardial  
57  
58  
59 17 infarction, arrhythmias, etc. may all contribute to the development of a cardiac arrest(11).

1 A previous study from Wuhan showed that 87.5% of COVID+ cases with in-hospital cardiac  
2 arrest had a respiratory etiology(5). We report much lower rates (24%), which may be due to  
3 several factors; e.g. in our study we had a total of 22 possible categories for cause of CA, as  
4 compared with two categories in the study from Wuhan. Also, patients in the study from  
5 Wuhan had severe COVID-19 and in our study population we do not know the severity of the  
6 disease.

7 The survival rates were poor among COVID+ patients with an overall 30-days survival of  
8 21%, compared to 36% among COVID-. The survival rate was, however, not as low as in the  
9 study from Wuhan, in which 3% (151 patients studied) survived, or in the study from New  
10 York with 31 patients with none surviving(5, 12). One reason for the poor survival could be  
11 the small number of patients found in a shockable rhythm (17% vs. 25% for COVID+ and  
12 COVID-, respectively) since patients with shockable rhythm have a more favorable outcome.

13 After adjusting for sex, age and shockable rhythm the 30-day survival was though still  
14 significantly worse among patients with an ongoing infection.

15 In our previous study we showed that COVID+ women had an odds ratio of 7.63  
16 (1.97–50.93) for 30-days mortality, as compared with COVID- women. The wide confidence  
17 interval in the previous study is mostly explained by lack of statistical power. In this study, in

1  
2  
3 1 which more patients were included, we demonstrate that COVID+ women had halved chance  
4  
5  
6  
7 2 of survival at 30 days, compared with COVID– women(6). We find it interesting that  
8  
9  
10 3 COVID+ women had acute MI three times as often as men, despite the fact that men  
11  
12  
13 4 exhibited shockable rhythm – and were defibrillated – twice as often as women; this cannot  
14  
15  
16  
17 5 be explained by differences in prevalent heart failure, as there were none across men and  
18  
19  
20 6 women.  
21  
22  
23

24 7 **Strengths and limitations.** This study includes all IHCA in Sweden which were reported to  
25  
26  
27 8 SRCR. The sample recorded in the SRCR is unbiased since all hospitals participate in the  
28  
29  
30 9 registry and all hospitals report data on COVID-19 status. However, we do not know the  
31  
32  
33  
34 10 severity of the COVID-19 infection, and we do not know if COVID-19 was the main reason  
35  
36  
37  
38 11 for admission to hospital. With regards to the classification of COVID-19 status, we have  
39  
40  
41 12 recently performed a misclassification analysis which demonstrated that odds ratios were not  
42  
43  
44 13 materially affected by misclassification bias. Our study only includes IHCA receiving CPR.  
45  
46  
47 14 This leaves out all other patients with IHCA, e.g with a Do Not Attempt Resuscitation order.  
48  
49  
50  
51 15 It is important to stress the fact that our regression model that included only COVID-19 cases  
52  
53  
54 16 must be interpreted with caution due to the large number of predictors in the model, which  
55  
56  
57  
58 17 had relatively few patients (resulting in wide confidence intervals). Further studies are  
59  
60

1 warranted, using a larger study population, and a longer follow up especially regarding  
2 subgroup analyses, neurological outcomes and the quality of life for the patients. Information  
3 about the severity of COVID-19 and the reason for admission to the hospital would add  
4 valuable insights as well.

## 5 **Conclusion**

6 During pandemic peaks, up to one fourth of all IHCA's are complicated by COVID-19, and  
7 these patients have halved chance of survival, with women displaying the worst outcomes.

8 While our previous study did not identify any COVID+ cases that were discharged alive, we  
9 now show that 19% of COVID+ cases are discharged alive, which is half the rate among  
10 COVID- cases.

## 11 **Funding**

12 This work was supported by the Swedish Research Council [2019-02019] and the Swedish  
13 Heart and Lung Foundation [20200261].

14 **Conflict of interest:** none declared.

15 **Author Statement:** Astrid Holm and Araz Rawshani designed the study. Astrid Holm has been  
16 the main author and been in charge of the analysis and interpretation of data. Araz Rawshani



1  
2  
3  
4 1 has been supervising. Matilda Jerkeman, Pedram Sultanian, Peter Lundgren, Annica Ravn-  
5  
6  
7 2 Fischer, Johan Israelsson, Jasna Giesecke and Johan Herlitz were all co-writers, revised  
8  
9  
10 3 the article critically for important intellectual content and approved the version of the article  
11  
12  
13 4 to be published.  
14  
15  
16  
17  
18

## 19 5 **References**

- 20  
21 6 1. Johns Hopkins University and Medicine COVID-19 map [internet] Johns Hopkins  
22 7 Coronavirus Resource Centre 2020. [updated 13/5/2021. Available from:  
23 8 <https://coronavirus.jhu.edu/map.html>.  
24 9 2. Dödsorsaker första halvåret 2020. Socialstyrelsen. Hälsa- och sjukvård.; 2020  
25 10 17/11/2020.  
26 11 3. Andersson J. Samhällsspridning av coronaviruset i Sverige. Läkartidningen.  
27 12 16/03/2020.  
28 13 4. Hayek SS, Brenner SK, Azam TU, Shadid HR, Anderson E, Berlin H, et al. In-hospital  
29 14 cardiac arrest in critically ill patients with covid-19: multicenter cohort study. *Bmj*. 2020;371:m3513.  
30 15 5. Shao F, Xu S, Ma X, Xu Z, Lyu J, Ng M, et al. In-hospital cardiac arrest outcomes among  
31 16 patients with COVID-19 pneumonia in Wuhan, China. *Resuscitation*. 2020;151:18-23.  
32 17 6. Sultanian P, Lundgren P, Strömsöe A, Aune S, Bergström G, Hagberg E, et al. Cardiac  
33 18 arrest in COVID-19: characteristics and outcomes of in- and out-of-hospital cardiac arrest. A report  
34 19 from the Swedish Registry for Cardiopulmonary Resuscitation. *European Heart Journal*. 2021.  
35 20 7. Hessulf F, Herlitz J, Rawshani A, Aune S, Israelsson J, Södersved-Källestedt ML, et al.  
36 21 Adherence to guidelines is associated with improved survival following in-hospital cardiac arrest.  
37 22 *Resuscitation*. 2020;155:13-21.  
38 23 8. Stef van Buuren, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained  
39 24 Equations in R. *Journal of Statistical Software*. 2011;Vol 45.  
40 25 9. 3.5 Classification and regression trees [Available from:  
41 26 <https://stefvanbuuren.name/fimd/sec-cart.html>.  
42 27 10. Nolan JP, Monsieurs KG, Bossaert L, Böttiger BW, Greif R, Lott C, et al. European  
43 28 Resuscitation Council COVID-19 guidelines executive summary. *Resuscitation*. 2020;153:45-55.  
44 29 11. Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al.  
45 30 Extrapulmonary manifestations of COVID-19. *Nat Med*. 2020;26(7):1017-32.  
46 31 12. Sheth V, Chishti I, Rothman A, Redlener M, Liang J, Pan D, et al. Outcomes of in-  
47 32 hospital cardiac arrest in patients with COVID-19 in New York City. *Resuscitation*. 2020;155:3-5.  
48  
49  
50  
51  
52  
53 33  
54  
55  
56  
57 34  
58  
59  
60

**Table 1** Characteristics of 1613 patients with IHCA during the COVID-19 pandemic.

Variables	No infection COVID –	Ongoing infection COVID +	Unknown/N A UNA	SMD
<b>n</b>	1062	182	369	
<b>Demographics:</b>				
Age - mean (SD)	71.00 (13.32)	70.93 (12.43)	70.22 (13.60)	0.039
Woman - n (%)	388 (36.6)	68 (37.6)	151 (41.0)	0.061
<b>Location of cardiac arrest - n (%)</b>				0.527
Coronary care unit - n (%)	155 (14.6)	14 ( 7.7)	50 (13.6)	
Intensive care unit - n (%)	77 ( 7.3)	25 (13.7)	19 ( 5.1)	
Operational room - n (%)	22 ( 2.1)	0 ( 0.0)	12 ( 3.3)	
Emergency room - n (%)	139 (13.1)	29 (15.9)	65 (17.6)	
Outpatient lab, radiology - n (%)	49 ( 4.6)	7 ( 3.8)	28 ( 7.6)	
Cathlab - n (%)	98 ( 9.2)	8 ( 4.4)	60 (16.3)	
Intermediate care unit - n (%)	25 ( 2.4)	15 ( 8.2)	10 ( 2.7)	
Regular ward - n (%)	468 (44.1)	82 (45.1)	116 (31.4)	
Other - n (%)	29 ( 2.7)	2 ( 1.1)	9 ( 2.4)	
<b>Critical times - median (IQR):</b>				
Time to alert – median (IQR)	1.00 [1.00, 1.00]	1.00 [1.00, 1.00]	1.00 [1.00,	0.078
Time to CPR - median (IQR)	0.00 [0.00, 1.00]	0.00 [0.00, 0.00]	0.00 [0.00,	0.109
Time to defibrillation - median (IQR)	2.00 [1.00, 5.00]	2.00 [1.00, 4.75]	1.00 [1.00,	0.141
<b>Comorbidities - n (%):</b>				
MI, ongoing - n (%)	178 (23.6)	12 (12.0)	37 (29.4)	0.292
MI, previous - n (%)	163 (20.8)	13 (11.7)	26 (18.4)	0.165
Stroke, ongoing - n (%)	30 ( 3.8)	4 ( 3.7)	4 ( 3.0)	0.030
Stroke, previous - n (%)	82 (10.3)	7 ( 6.1)	15 (10.5)	0.105
Cancer, any - n (%)	165 (20.9)	20 (17.7)	28 (20.6)	0.054
Diabetes - n (%)	224 (27.9)	36 (31.0)	38 (27.0)	0.060
Heart failure - n (%)	229 (29.7)	36 (33.0)	36 (27.9)	0.074
Ejection fraction (%) - mean (SD)	46.14 (13.74)	46.44 (11.86)	44.94 (14.82)	0.073
EF <50% - n (%)	167 (46.0)	26 (48.1)	22 (46.8)	0.029
<b>Kidney function category - n (%)</b>				0.121
eGFR <30 - n (%)	165 (21.6)	22 (20.0)	26 (20.0)	
eGFR 30–59- n (%)	216 (28.3)	32 (29.1)	44 (33.8)	
eGFR 60–89 - n (%)	198 (25.9)	25 (22.7)	30 (23.1)	
eGFR ≥90 - n (%)	185 (24.2)	31 (28.2)	30 (23.1)	
No kidney failure (eGFR ≥60) - n (%)	383 (50.1)	56 (50.9)	60 (46.2)	0.063
eGFR (ml/min/m2) - mean (SD)	66.89 (49.43)	71.26 (58.96)	63.78 (40.31)	0.099
<b>Cause of arrest: - n (%)</b>				0.629
Hemorrhage - n (%)	34 (4.9)	2 (2.0)	10 (8.1)	
Myocardial infarction/ischemia- n (%)	181 (26.2)	15 (14.9)	41 (33.3)	
Other - n (%)	213 (30.8)	30 (29.7)	41 (33.3)	
Primary arrhythmia - n (%)	101 (14.6)	8 (7.9)	12 (9.8)	
Respiratory insufficiency - n (%)	73 (10.5)	24 (23.8)	7 (5.7)	
Sepsis/infection - n (%)	45 (6.5)	19 (18.8)	4 (3.3)	

Stroke/thromboembolism - n (%)	45 (6.5)	3 (3.0)	8 (6.5)	
<b>Early interventions - n (%):</b>				
Witnessed arrest - n (%)	857 (80.9)	140 (77.8)	306 (85.0)	0.124
ECG monitoring - n (%)	635 (60.5)	89 (50.0)	221 (62.1)	0.163
CPR before AGA - n (%)	845 (91.0)	146 (93.6)	268 (88.2)	0.127
Defibrillated before AGA - n (%)	159 (17.9)	18 (11.9)	53 (19.0)	0.131
Ventilated before AGA - n (%)	503 (63.2)	74 (54.8)	175 (69.2)	0.199
Shockable rhythm - n (%)	247 (24.9)	29 (17.3)	90 (27.0)	0.158
Defibrillated, any - n (%)	323 (31.5)	40 (22.7)	111 (32.8)	0.151
Intubated - n (%)	473 (47.0)	100 (57.8)	177 (53.8)	0.145
Adrenaline given - n (%)	668 (65.6)	125 (72.7)	223 (66.4)	0.102
Antiarrhythmics - n (%)	139 (14.1)	17 (10.1)	48 (15.4)	0.107
Mechanical compressions - n (%)	109 (10.8)	18 (10.4)	66 (20.0)	0.180
Active temperature control - n (%)	54 (11.3)	5 (10.4)	3 (4.4)	0.173
<b>Status at rescue team arrival - n (%):</b>				
Consciousness - n (%)	214 (23.1)	18 (11.7)	57 (19.3)	0.204
Breathing - n (%)	288 (31.2)	30 (19.5)	84 (28.7)	0.181
Pulse - n (%)	309 (33.8)	36 (23.4)	89 (30.4)	0.154
<b>Follow-Up data - n (%):</b>				
Angiography - n (%)	115 (24.2)	8 (16.7)	15 (20.8)	0.124
PCI - n (%)	87 (18.2)	4 ( 8.3)	16 (21.9)	0.258
Pacemaker implanted - n (%)	80 (16.7)	2 ( 4.2)	4 ( 5.6)	0.281
ICD implanted - n (%)	36 ( 7.5)	1 ( 2.1)	2 ( 2.8)	0.172
ROSC - n (%)	520 (49.0)	64 (35.2)	142 (38.5)	0.188
Death at 30 days - n (%)	666 (62.7)	141 (77.5)	237 (64.2)	0.218
Death overall - n (%)	703 (66.2)	141 (77.5)	241 (65.3)	0.181
Discharged alive - n (%)	283 (35.6)	22 (19.0)	39 (26.5)	0.253

**SD = standard deviation; IQR = interquartile range; SMD = standardized mean difference (difference between the means for the two groups divided by their mutual standard deviation. Values below 0.1 (10%) are considered inconsequential (i.e., no significant difference between the groups)). CPR = Cardiopulmonary resuscitation, PCI = Percutaneous Coronary Intervention, ICD = implantable cardioverter-defibrillator. ROSC = return of spontaneous circulation. AGA= alarm group arrival**

1

2

## 1 **Figure Titles and Legends**

### 2 **Figure 1: Characteristics of IHCA according to COVID-19 status**

3 A: Monthly proportion of COVID-19 status among patients with IHCA, stratified on COVID-  
4 19 status. In March only cases after 15/03/2020 were included.

5 B: Etiology of IHCA, stratified on COVID-19 status. The y-axis shows percentages for each  
6 etiology in each group.

7 C: Clinical conditions 1 hour prior to IHCA, stratified on COVID-19 status. Only patients  
8 with data regarding the specific condition was included.

### 9 **Figure 2: Kaplan Meier survival curves**

10 Kaplan Meier survival curves, separately for (A)Overall, (B)Women, (C)Men, (D)Age  $\geq 70$   
11 year, (E)Age  $< 70$  year, (F)Cancer, (G)Heart failure, (H)Diabetes, (I)Kidney failure and  
12 (J)Myocardial infarction.  $p = \log$ -rank  $p$ -value. The numbers under the graphs are showing the  
13 survival in percentages. Regarding myocardial infarction acute MI is presented.

### 14 **Figure 3: Odds Ratio for 30-day survival**

15 Forest plot with the adjusted odds ratio for 30-day survival among patients with ongoing  
16 infection vs. no infection and unknown/NA vs. no infection. Stratified on overall, men,

1  
2  
3  
4 1 women, age < 70 years, age ≥ 70 years, heart failure, kidney failure, diabetes, myocardial  
5  
6  
7 2 infarction and cancer. Myocardial infarction was defined as acute or previous MI.  
8  
9

10  
11 3 **Figure 4: Odds Ratio for 30-day survival**  
12

13  
14 4 Forest plot with odds ratio for 30-day survival, stratified on the groups, no infection, ongoing  
15  
16  
17 5 infection and overall, all in different colors. The 95% Confidence interval is shown between  
18  
19  
20  
21 6 the bars. X-axis has a logarithmic scale. ECG=electrocardiogram, CA=cardiac arrest,  
22  
23  
24 7 MI=myocardial infarction. CI=confidence interval.  
25  
26  
27

28  
29 8  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Figure 1: Characteristics of IHCA according to COVID-19 status




Figure 1A: Monthly proportion of COVID-19 status among patients with IHCA, stratified on COVID-19 status. In March only cases after 15/03/2020 were included.






Figure 1B: Etiology of IHCA, stratified on COVID-19 status. The y-axis shows percentages for each etiology in each group.



**Figure 1C: Clinical conditions 1 hour prior to IHCA, stratified on COVID-19 status. Only patients with data regarding the specific condition was included.**


Figure 2: Kaplan Meier survival curves



**Figure 2: Kaplan Meier survival curves, separately for (A) Overall, (B) Women, (C) Men, (D) Age ≥70 year, (E) Age <70 year, (F) Cancer, (G) Heart failure, (H) Diabetes, (I) Kidney failure and (J) Myocardial infarction. p= log-rank p-value. The numbers under the graphs are showing the survival in percentages. Regarding myocardial infarction acute MI is**



Figure 3: Odds Ratio for 30-day survival



**Figure 3: Forest plot with the adjusted odds ratio for 30-day survival among patients with ongoing infection vs. no infection and unknown/NA vs. no infection.** Stratified on overall, men, women, age < 70 years, age ≥ 70 years, heart failure, kidney failure, diabetes, myocardial infarction and cancer. Myocardial infarction was defined as acute or previous MI.

Figure 4: Odds Ratio for 30-day survival




Figure 4: Forest plot with odds ratio for 30-day survival, stratified on the groups, no infection, ongoing infection and overall, all in different colors. The 95% Confidence interval is shown between the bars. X-axis has a logarithmic scale. ECG= electrocardiogram, CA= cardiac arrest, MI= myocardial infarction. CI= confidence interval.

1  
2  
3  
4 **Supplementary figures and tables**  
5

6  
7 **Characteristics and Outcomes in Patients**  
8 **with COVID-19 and In-Hospital Cardiac**  
9 **Arrest**  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Supplementary Table 1: Characteristics of COVID+ patients with IHCA in relation to sex.


**Supplementary Table 1:** Characteristics of 181 COVID+ patients with IHCA during the COVID-19 pandemic in relation to sex. One COVID+ patient had missing data on sex.

variables	Men	Women	SMD
<b>n</b>	113	68	
<b>Demographics:</b>			
Age - mean (SD)	71.39 (10.75)	70.35 (14.87)	0.080
<b>Location of cardiac arrest - n (%):</b>			0.249
Coronary care unit	7 ( 6.2)	7 ( 10.3)	
Intensive care unit	15 (13.3)	10 ( 14.7)	
Operational room	0 ( 0.0)	0 ( 0.0)	
Emergency room	17 (15.0)	11 ( 16.2)	
Outpatient lab, radiology	4 ( 3.5)	3 ( 4.4)	
Cathlab	6 ( 5.3)	2 ( 2.9)	
Intermediate care unit	11 ( 9.7)	4 ( 5.9)	
Regular ward	52 (46.0)	30 ( 44.1)	
Other	1 ( 0.9)	1 ( 1.5)	
<b>Critical times - median (IQR):</b>			
Time to alert – median (IQR)	1.00 [1.00, 1.00]	1.00 [1.00, 1.00]	0.256
Time to CPR - median (IQR)	0.00 [0.00, 0.00]	0.00 [0.00, 1.00]	0.031
Time to defibrillation - median	2.00 [1.00, 5.00]	2.00 [1.00, 2.00]	0.009
<b>Comorbidities - n (%):</b>			
MI, ongoing - n (%)	5 ( 7.6)	7 ( 21.2)	0.396
MI, previous - n (%)	11 (16.4)	2 ( 4.7)	0.391
Stroke, ongoing - n (%)	4 ( 5.8)	0 ( 0.0)	0.351
Stroke, previous - n (%)	5 ( 7.0)	2 ( 4.7)	0.102
Cancer, any - n (%)	13 (18.8)	6 ( 14.0)	0.132
Diabetes - n (%)	24 (33.3)	12 ( 27.9)	0.118
Heart failure - n (%)	23 (33.8)	13 ( 32.5)	0.028
Ejection fraction (%) - mean (SD)	44.84 (12.22)	49.31 (10.56)	0.392
EF <50% - n (%)	19 (51.4)	7 ( 43.8)	0.153
<b>Kidney function category - n (%):</b>			0.357
eGFR <30	16 (22.9)	6 ( 15.0)	
eGFR 30–59	17 (24.3)	15 ( 37.5)	
eGFR 60–89	18 (25.7)	7 ( 17.5)	
eGFR ≥90	19 (27.1)	12 ( 30.0)	
No kidney failure (eGFR ≥60)	37 (52.9)	19 ( 47.5)	0.107
eGFR (ml/min/m <sup>2</sup> ) - mean (SD)	72.72 (65.75)	68.70 (45.34)	0.071
<b>Cause of arrest - n (%):</b>			0.920
Hemorrhage	1 ( 1.5)	1 ( 2.9)	
Myocardial infarction/ischemia	7 (10.6)	8 ( 23.5)	
Other	18 (27.3)	12 ( 35.3)	
Primary arrhythmia	3 ( 4.5)	5 ( 14.7)	
Respiratory insufficiency	17 (25.8)	7 ( 20.6)	

Sepsis / infection	18 (27.3)	1 ( 2.9)	
Stroke / thromboembolism	2 ( 3.0)	0 ( 0.0)	
<b>Early interventions - n (%):</b>			
Witnessed arrest - n (%)	86 (76.8)	53 ( 79.1)	0.056
ECG monitoring - n (%)	56 (50.5)	33 ( 50.0)	0.009
CPR before AGA - n (%)	90 (92.8)	55 ( 94.8)	0.085
Defibrillated before AGA - n (%)	13 (13.8)	5 ( 8.9)	0.155
Ventilated before AGA- n (%)	49 (56.3)	25 ( 53.2)	0.063
Shockable rhythm - n (%)	22 (20.8)	7 ( 11.5)	0.254
Defibrillated, any - n (%)	29 (26.4)	11 ( 16.9)	0.231
Intubated - n (%)	61 (57.0)	38 ( 58.5)	0.029
Adrenaline given - n (%)	76 (70.4)	48 ( 76.2)	0.132
Antiarrhythmics - n (%)	11 (10.4)	6 ( 9.7)	0.023
Mechanical compressions - n (%)	12 (10.9)	5 ( 8.1)	0.097
Active temperature control - n (%)	2 (6.1)	3 ( 20.0)	0.423
<b>Status at rescue team arrival - n</b>			
Consciousness - n (%)	11 (11.3)	6 (10.7)	0.020
Breathing - n (%)	18 (18.6)	11 (19.6)	0.028
Pulse - n (%)	22 (22.7)	13 (23.2)	0.013
<b>Follow-Up data - n (%):</b>			
Angiography - n (%)	4 (12.1)	4 (26.7)	0.374
PCI - n (%)	2 (6.1)	2 (13.3)	0.248
Pacemaker implanted - n (%)	0 (0.0)	2 (13.3)	0.555
ICD implanted - n (%)	0 (0.0)	1 ( 6.7)	0.378
ROSC - n (%)	40 (35.4)	24 (35.3)	0.002
Death at 30 days - n (%)	85 (75.2)	56 (82.4)	0.175
Death overall - n (%)	85 (75.2)	56 (82.4)	0.175
Discharged alive - n (%)	16 (22.2)	6 (14.0)	0.216


**SD = standard deviation; IQR = interquartile range; SMD = standardized mean difference (difference between the means for the two groups divided by their mutual standard deviation. Values below 0.1 (10%) are considered inconsequential (i.e., no significant difference between the groups)). CPR = cardiopulmonary resuscitation, PCI = percutaneous coronary intervention, ICD = implantable cardioverter-defibrillator. ROSC = return of spontaneous circulation. AGA= alarm group arrival.**

Supplementary Figure 1: Missing data before and after imputation with MICE




**Supplementary Figure 1: Missing data before and after imputation with MICE.** A graphical view of the entire dataset is printed. Each column (variable) is depicted at the top and column color depicts type of variable. Each patient represents a row and white gaps indicate a missing data entry.

Supplementary Figure 2: Flow chart



**Supplementary Figure 2: Flow chart of the study population.** Patients who were less than 18 year of age, and cases occurring in the pre-pandemic period were excluded.


Supplementary Figure 3: Information on COVID-19 status during the study period.



**Supplementary Figure 3: Information on COVID-19 status during the study period.** No equals missing data, i.e. no information on COVID-19 status available. Yes equals, COVID +, COVID – or Unknown. In March only cases after 15/03/2020 were included.




Supplementary Figure 4: Distribution of age




Supplementary Figure 4: Distribution of age in relation to COVID-19 status.

Supplementary Figure 5: Etiology of IHCA, according to sex




Supplementary Figure 5A: Etiology of IHCA, men only.




Supplementary Figure 5B: Etiology of IHCA, women only.

## Supplementary Figure 6: Conditions preceding IHCA, according to sex




## Supplementary Figure 6A: Conditions preceding IHCA, men only.



## Supplementary Figure 6B: Conditions preceding IHCA, women only.

Supplementary Figure 7: Cox adjusted survival curve for the overall population



Supplementary Figure 7: Cox adjusted survival curve for the overall population, stratified on COVID-19 status.

## STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page No
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2-3
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	2
Objectives	3	State specific objectives, including any prespecified hypotheses	2
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	2
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	2
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	2
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	2
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5-6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5
Bias	9	Describe any efforts to address potential sources of bias	3-4
Study size	10	Explain how the study size was arrived at	5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5-6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6-7
		(b) Describe any methods used to examine subgroups and interactions	6-7
		(c) Explain how missing data were addressed	6-7
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	6-7
		(e) Describe any sensitivity analyses	6-7

Continued on next page

<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7
		(b) Give reasons for non-participation at each stage	7
		(c) Consider use of a flow diagram	Supplementary material
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	7-8
		(b) Indicate number of participants with missing data for each variable of interest	7-8
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	7
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	8-9
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	7-10
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Supplementary material
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	11
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	13-14
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11-14
Generalisability	21	Discuss the generalisability (external validity) of the study results	14
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	14

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

For peer review only

# BMJ Open

## A Cohort Study of the Characteristics and Outcomes in Patients with COVID-19 and In-Hospital Cardiac Arrest

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-054943.R1
Article Type:	Original research
Date Submitted by the Author:	30-Sep-2021
Complete List of Authors:	<p>Holm, Astrid; University of Gothenburg, Department of Molecular and Clinical Medicine            Jerkeman, Matilda; University of Gothenburg, Department of Molecular and Clinical Medicine            Sultanian, Pedram; University of Gothenburg, Department of Molecular and Clinical Medicine            Lundgren, Peter; University of Gothenburg, Department of Molecular and Clinical Medicine; Kalmar County Hospital, Department of Internal Medicine            Ravn-Fischer, Annica; University of Gothenburg, Department of Molecular and Clinical Medicine            Israelsson, Johan; Kalmar County Hospital, Department of Internal Medicine; Linnaeus University, Faculty of Health and Life Sciences            Giesecke, Jasna; Danderyd University Hospital            Herlitz, Johan; University of Borås, Centre for Prehospital Research            Rawshani, Araz; University of Gothenburg, Department of Molecular and Clinical Medicine</p>
<b>Primary Subject Heading</b>:	Cardiovascular medicine
Secondary Subject Heading:	Cardiovascular medicine, Infectious diseases
Keywords:	COVID-19, CARDIOLOGY, Adult cardiology < CARDIOLOGY, Coronary heart disease < CARDIOLOGY

SCHOLARONE™  
Manuscripts





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

# A Cohort Study of the Characteristics and Outcomes in Patients with COVID-19 and In-Hospital Cardiac Arrest

Astrid Holm, MD<sup>1</sup>, Matilda Jerkeman, MD<sup>1</sup>, Pedram Sultanian, MD<sup>1</sup>, Peter Lundgren, MD, PhD<sup>1,3,7</sup>, Annica Ravn-Fischer, MD, PhD, Docent<sup>1</sup>, Johan Israelsson, PhD<sup>3,4</sup>, Jasna Giesecke, RN<sup>5</sup>, Johan Herlitz, MD, PhD<sup>2,6</sup>, Araz Rawshani, MD, PhD<sup>1,2</sup>

## Affiliations:

<sup>1</sup>Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden

<sup>2</sup>The Swedish Registry for Cardiopulmonary Resuscitation, Centre of Registries, Västra Götaland County, Sweden

<sup>3</sup>Department of Internal Medicine, Division of Cardiology, Kalmar County Hospital, Region Kalmar County, Sweden

<sup>4</sup>Faculty of Health and Life Sciences, Linnaeus University, Kalmar, Sweden

<sup>5</sup>RN, Lead CPR coordinator, Clinicum- Centre for clinical skills, interprofessional education and advanced medical simulation, Danderyd University Hospital, Stockholm, Sweden

<sup>6</sup>Prehospiten – Centre for Prehospital Research, University of Borås, Borås, Sweden

<sup>7</sup>Region Västra Götaland, Sahlgrenska University Hospital, Department of Cardiology, Gothenburg, Sweden

## Contact information:

Astrid Holm

Email: [astrid.holm@gu.se](mailto:astrid.holm@gu.se)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Phone: +358 400707722

**Manuscript word count:** 3442

## Key Points

**Question:** What are the Characteristics, causes and outcomes in patients with COVID-19 who suffer an in-hospital cardiac arrest (IHCA)?

**Findings:** In the registry-based observational study we found that during pandemic peaks, up to one fourth of all IHCAs are complicated by COVID-19, and these patients have halved chance of survival.

**Meaning:** The survival rate of patients with COVID-19 associated IHCA is low with women displaying the worst outcomes.

## Abstract

**Objective:** We studied characteristics, survival, causes of cardiac arrest, conditions preceding cardiac arrest, predictors of survival, and trends in the prevalence of COVID-19 among IHCA cases. Data on characteristics and outcomes in patients with COVID-19 who suffer an in-hospital cardiac arrest (IHCA) is scarce.

**Design and setting:** Registry-based observational study.

**Participants:** We studied all cases of IHCA receiving CPR ( $\geq 18$  years of age) in the Swedish Registry for Cardiopulmonary Resuscitation from 15/03/2020 to 31/12/2020. A total of 1613

1  
2  
3 patients were included and divided into the following groups: ongoing infection (**COVID+**;  
4  
5  
6 n=182), no infection (**COVID-**; n=1062) and unknown/not assessed (**UNA**; n=369).  
7  
8  
9

10 **Main outcomes and measures:** We studied monthly trends in proportions of COVID-19  
11  
12 associated IHCAs, causes of IHCA in relation to COVID-19 status, clinical conditions  
13  
14 preceding the cardiac arrest and predictors of survival.  
15  
16  
17  
18  
19  
20

21 **Results:** The rate of COVID+ patients suffering an IHCA increased to 23% during the first  
22  
23 pandemic wave (April), then abated to 3% in July, and then increased to 19% during the  
24  
25 second wave (December). Among COVID+ cases, 43% had respiratory insufficiency or  
26  
27 infection as the underlying cause of the cardiac arrest, compared to 18% among COVID-  
28  
29 cases. The most common clinical sign preceding cardiac arrest was hypoxia (57%) among  
30  
31 COVID+ cases. Odds ratio for 30-day survival for COVID+ cases was 0.50 (95% CI 0.33-  
32  
33 0.76) compared with COVID- cases.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

45 **Conclusion:** During pandemic peaks, up to one fourth of all IHCAs are complicated by  
46  
47 COVID-19, and these patients have halved chance of survival, with women displaying the  
48  
49 worst outcomes.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Article Summary

### Strengths and limitations of this study

- A major strength of our study is that it includes all IHCA in Sweden which were reported to the Swedish Registry for Cardiopulmonary Resuscitation.
- The sample recorded in the Swedish Registry for Cardiopulmonary Resuscitation is unbiased since all hospitals participate in the registry and all hospitals report data on COVID-19 status
- A limitation is that we do not know the severity of the COVID-19 infection, and we do not know if COVID-19 was the main reason for admission to hospital.
- Our study only includes IHCA receiving CPR which leaves out all other patients with IHCA, e.g with a Do Not Attempt Resuscitation order.
- It is important to stress the fact that our regression model that included only COVID-19 cases must be interpreted with caution due to the large number of predictors in the model, which had relatively few patients.

## Introduction

The COVID-19 pandemic has, as of May 1<sup>st</sup> 2021 infected over 159,000,000 persons and lead to the demise of over 3,321,000 individuals(1).The Swedish Public Health Authority declared on March 16<sup>th</sup> 2020 that community spread of COVID-19 had commenced, and COVID-19 is now the third leading cause of death in Sweden(2, 3).

Multiple studies have showed that in-hospital cardiac arrest (IHCA) among patients with COVID-19 is associated with poor survival(4-7). In a study from the U.S. with 260 patients hypoxia was the main cause to Cardiac arrest among over 40% of the patients with COVID-19 and IHCA (6).We studied IHCA in the Swedish Registry for Cardiopulmonary Resuscitation (SRCR) and showed a 2.3-fold increase in 30-day mortality among cases with COVID-19 compared to pre-pandemic cases and this was mainly driven by a 9-fold increase in mortality among women with COVID-19. During the study period no case of IHCA with COVID-19 was discharged alive from the hospital(8).

The current study expands our previous investigation, including more patients, longer follow-up and emphasizes the causes of cardiac arrest in COVID-19, predictors of survival, coexisting conditions, and trends in the prevalence of COVID-19 among IHCA cases.

## Methods

### Data sources

The study is a registry-based observational study with data obtained from the SRCR during the time period 15/03/2020 to 31/12/2020.

The SRCR is a national quality registry and has included IHCA cases since 2005. The data is collected by trained nurses who report patient data using a web-based protocol. The registry has previously been described in detail(9). Vital status was obtained from the Swedish Population Registry and the last day of follow up was 31/12/2020.

### Study population

The study population included all patients  $\geq 18$  years of age suffering from IHCA and receiving CPR throughout Sweden during the period 15/03/2020 to 31/12/2020. We used 15th of March as the start date of the pandemic as the Swedish Public Health Authority declared on March 16<sup>th</sup> 2020 that COVID-19 was community spread in Sweden(3). On 1<sup>st</sup> of April the SRCR started collecting data about COVID-19 status, and retrospectively identified 60 patients with COVID-19 who suffered IHCA during March (they were included in the study). Patients were divided into the following three groups: ongoing infection (COVID+; n=182), no infection (COVID-; n=1062) and unknown/not assessed (UNA; n=369). COVID+ was



1  
2  
3 defined as patients registered with an ongoing COVID-19 infection, suspected ongoing  
4  
5  
6  
7 infection or patients with a recent infection(n=29).  
8  
9

## 10 11 **Variable definitions** 12

13  
14 In SRCR a patient with cardiac arrest was defined as an unconscious patient with no or  
15  
16 abnormal breathing, in whom resuscitation or defibrillation was attempted. IHCA was defined  
17  
18 as cardiac arrest in patients admitted to the hospital.  
19  
20  
21  
22

23  
24 With regards to previous coexisting conditions heart failure was defined as any heart failure  
25  
26 described before cardiac arrest. Kidney failure was defined as estimated glomerular filtration  
27  
28 rate (eGFR) below 60 ml/min/1.73 m<sup>2</sup>, calculated using the highest creatinine before cardiac  
29  
30 arrest with Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula based  
31  
32 on sex, age and creatinine. The SRCR records data on the highest creatinine levels analyzed  
33  
34 up to six months prior to CA. Diabetes was defined as any diabetes diagnosis, regardless of  
35  
36 type. Cancer was defined as any previously known cancer. Acute myocardial infarction (MI)  
37  
38 was defined as an MI within 72 hours of CA. **Previous** myocardial infarction was defined as  
39  
40 MI occurring earlier than 72 hours preceding the CA.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52

53  
54 Regarding clinical conditions one hour prior to CA, arrhythmia was defined as any  
55  
56 arrhythmia, hypoxia was defined as an oxygen saturation below 90%, hypotension was  
57  
58  
59  
60

1  
2  
3 defined as systolic blood pressure below 90 mmHg, seizure was defined as any seizure with  
4  
5  
6  
7 loss of consciousness, and heart failure was defined as any heart failure with pulmonary  
8  
9  
10 edema or severe shortness of breath with rales.

11  
12  
13 A monitored ward was defined as a coronary care unit(CCU), an intensive care unit(ICU), an  
14  
15  
16 operational room(OR), an emergency room(ER), an intermediate care unit(IMCU) or a  
17  
18  
19 catheterization laboratory(Cath lab). A non-monitored ward was defined as a regular ward  
20  
21  
22  
23 (RW). All other wards were defined as other ward, e.g. outpatient lab, radiology department,  
24  
25  
26  
27 etc.

### 31 **Statistical analyses**

32  
33 Patient characteristics are reported in means and medians, along with standard deviations and  
34  
35  
36 interquartile ranges, respectively. The Kaplan-Meier estimator was used for defining survival  
37  
38  
39  
40 distributions; the log rank test was used to test for differences in survival. Trends in rates of  
41  
42  
43  
44 COVID-19 were assessed on a monthly basis during the entire study basis.

45  
46  
47 Logistic regression was used to calculate odds ratios for 30-days survival. These models  
48  
49  
50  
51 assessed the association between COVID-19 status and 30-days survival, while adjusting for  
52  
53  
54 age, sex and initial rhythm (shockable or non-shockable). Subgroup analyzes were done for  
55  
56  
57  
58  
59  
60

1  
2  
3 men, women, age  $\geq 70$  years, age  $< 70$  years, heart failure, kidney failure, diabetes, myocardial  
4  
5  
6 infarction and cancer.  
7  
8  
9

10 In order to obtain estimates of overall survival, we used Cox proportional hazards model with  
11  
12 hours since CA as the time scale. The proportional hazards assumption was fulfilled for all  
13  
14  
15  
16  
17 variables.  
18  
19

20  
21 We used the MICE (Multiple Imputation By Chained Equations) algorithm to impute missing  
22  
23 values(10, 11) (Supplementary Figure 1). The imputed data set was used to calculate odds  
24  
25  
26  
27 ratios for 30-days survival in the overall group, as well as in COVID+ and COVID- cases.  
28  
29

30  
31 These models included age, sex, initial rhythm, time to start of cardiopulmonary resuscitation  
32  
33 (CPR), time of CA, previous MI, location (other ward vs monitored, and non-monitored ward  
34  
35 vs monitored), heart failure, EKG monitoring, diabetes and acute MI.  
36  
37  
38  
39

40  
41  
42 Analyses were done in R (v. 4.0.3, R Foundation for Statistical Computing) using RStudio.  
43  
44  
45

#### 46 **Patient and Public Involvement statement:**

  
47

48 No patients were involved.  
49  
50  
51  
52  
53

#### 54 **Results**

  
55

56 A total of 2,227 patients were enrolled in the SRCR between 01/01/2020 and 31/12/2020.  
57  
58  
59

60 After excluding patients  $< 18$  years (n=68) and pre-pandemic cases (n=546), 1,613 cases

1  
2  
3 remained from 15/03/2020 to 31/12/2020 and constituted the final study population

4  
5  
6 (Supplementary Figure 2). There was a high rate of information on COVID-19 status during

7  
8  
9 the study period among patients registered in the registry (Supplementary Figure 3).

### 10 11 12 13 14 **Baseline characteristics**

15  
16 The overall mean age was 70.8 years, and the proportion of women was 37.6%. At the end of

17  
18  
19 follow-up, 341 (32.7%) patients were alive. The mean age was similar in the three groups:

20  
21  
22  
23 70.9 years among COVID+, 71.0 years among COVID– cases, and 70.2 years in cases with

24  
25  
26 UNA (Supplementary Figure 4). The proportion of women was also similar; 37.6% in

27  
28  
29 COVID+, 36.6% in COVID– and 41.0% in UNA cases.

30  
31  
32  
33 A regular ward (RW) was the most common place of cardiac arrest in all 3 groups with rates

34  
35  
36 of 45.1% among COVID+, 44.1% among COVID– and 31.4% among UNA (Table 1). The

37  
38  
39 emergency room (ER) was the second most common location for COVID+ cases (15.9%).

40  
41  
42  
43 The ER was the location of cardiac arrest in 17.6% of UNA cases and 13.1% for COVID–

44  
45  
46 cases.

47  
48  
49  
50 Regarding comorbidities, acute myocardial infarction was observed in 12.0% of COVID+ and

51  
52  
53  
54 23.6% of COVID– cases. Previous myocardial infarction was observed in 11.7% of COVID+,

1  
2  
3 20.8% of COVID– and 11.7% of UNA cases. The prevalence of heart failure, cancer and  
4  
5  
6  
7 diabetes was similar across all groups (Table 1).  
8  
9

10 Fewer cases among COVID+ individuals had a shockable rhythm (17.3%), compared with  
11  
12  
13 COVID– (24.9%) and UNA (27.0%). Likewise, fewer cases among COVID+ (22.7%) were  
14  
15  
16  
17 defibrillated, compared with COVID– (31.5%) and UNA (32.8%). COVID+ cases were  
18  
19  
20 ventilated in 54.8% of cases before rescue team arrival, as compared with 63.2% and 69.2%  
21  
22  
23  
24 in COVID– and UNA, respectively.  
25  
26  
27

## 28 **Follow-up and**

29  
30 Return of spontaneous circulation (ROSC) after initial resuscitation, was less common in  
31  
32  
33 COVID+ cases, as compared with COVID– and UNA. Also, angiography, PCI, pacemaker  
34  
35  
36  
37 and ICD implantation post cardiac arrest were less common in COVID+ cases.  
38  
39  
40  
41  
42  
43  
44

## 45 **Sex specific characteristics**

46  
47  
48 Acute myocardial infarction was observed in 21.2% of COVID+ women and 7.6% of  
49  
50  
51 COVID+ men. Previous myocardial infarction was observed in 4.7% of COVID+ women and  
52  
53  
54 16.2% of COVID+ men. The prevalence of previous stroke, renal failure, heart failure, cancer  
55  
56  
57  
58 and diabetes were similar among men and women, as was location at the time of cardiac  
59  
60

1  
2  
3 arrest. COVID+ men were more likely to have a shockable rhythm (20.8%) compared with  
4  
5  
6 COVID+ women (11.5%) and to be defibrillated (26.4% in men vs 16.9% in women)  
7  
8  
9  
10 (Supplementary Table 1).

### 11 12 13 14 **Monthly trends in COVID-19 associated IHCA**

15  
16 In March, April and May 14%, 23% and 20% of patients suffering IHCA were COVID+ (data  
17  
18 from 16<sup>th</sup> March). The proportion of COVID+ cases diminished rapidly during June to July.  
19  
20  
21 From September onwards the COVID+ cases increased again to reach 19% in December. In  
22  
23  
24  
25  
26  
27 Figure 1A additional details regarding monthly variations are presented.

### 28 29 30 31 **Etiology of IHCA**

32  
33 The most common cause of IHCA among COVID+ was respiratory insufficiency (24%,  
34  
35 n=24). The second most common cause was sepsis or other infection (19%, n=19) among  
36  
37  
38 COVID+. Respiratory insufficiency and sepsis/other infection were less common in the other  
39  
40  
41  
42  
43  
44  
45  
46  
47 groups (Figure 1B), which instead displayed higher rates of acute myocardial infarction.

### 48 49 50 51 **Clinical conditions one hour prior to IHCA**

52  
53 As evident in Figure 1C which describes the clinical conditions preceding (up to 60 minutes)  
54  
55  
56  
57  
58  
59  
60 the cardiac arrest, hypoxia was more common among COVID+ (57%), as compared with

1  
2  
3 COVID– (34%). Regarding arrhythmia, heart failure, hypotension and seizure the percentages  
4  
5  
6  
7 were more similar.  
8  
9

## 10 **Survival analysis**

11  
12  
13 The Kaplan Meier plots (Figure 2) show that COVID+ cases generally had a lower  
14  
15  
16 probability of survival compared to COVID– and UNA cases. The overall 30-day survival  
17  
18  
19 (Figure 2A) was 21% among COVID+, compared with 36% in COVID– cases ( $p=0.00086$ ).  
20  
21  
22

23 The subgroup analysis of women (Figure 2B) showed low survival rates in COVID+ cases  
24  
25  
26 (16% 30-day survival). The subgroup analysis of men (Figure 2C) showed low survival rates  
27  
28  
29 in COVID+ cases (23% 30-day survival) but not as low as the women. Regarding age, 30  
30  
31  
32 days survival among COVID+ aged >70 years was 18% (Figure 2D), as compared with 25%  
33  
34  
35 of COVID+ cases aged 70 or younger (Figure 2E). Survival curves for the subgroups of  
36  
37  
38 individuals with cancer, heart failure and diabetes, did not display any clear patterns (Figure  
39  
40  
41  
42  
43 2F-2H). All p values were >0.1. Patients with kidney failure had a 30 days survival of 13%  
44  
45  
46 among COVID+ cases (Figure 2I). Patients with acute MI had a 30 days survival of 8%  
47  
48  
49 among COVID+ cases (Figure 2J).  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Cox adjusted survival curves are presented in Supplementary Figure 5; COVID+ cases  
4  
5  
6  
7 displayed the lowest probability of survival, whereas there was no material difference  
8  
9  
10 between COVID- and UNA cases.  
11  
12

### 13 **Odds ratios for 30-days survival**

14  
15  
16 When adjusted for age, sex and initial rhythm the odds ratio for 30-day survival, comparing  
17  
18  
19 COVID+ vs. COVID-, were 0.50 (0.33-0.76) overall, 0.53 (0.31-0.88) for men, and 0.44  
20  
21  
22 (0.20-0.88) for women. In the subgroup of patients with heart failure, myocardial infarction  
23  
24  
25  
26 and cancer, we found no statistically significant associations, whereas in the subgroup of  
27  
28  
29 COVID+ patients with kidney failure, odds ratio for 30-days survival was 0.43 (0.16-0.99),  
30  
31  
32 when compared with COVID- (Figure 3).  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## Predictors of survival

Regarding predictors for 30-days survival among COVID+ we note that confidence intervals were generally wide. Lack of ECG monitoring and later start of CPR showed point estimates below 1.0, although non-significant. Odds ratio for patients treated in non-monitored wards was 0.26 (95% CI 0.08-0.78) as compared with monitored ward(Figure 4). No coexisting condition was associated with survival among COVID+ cases.

Regarding COVID- cases the factors that were significantly associated with 30-days survival were shockable rhythm (OR 4.18 [95% CI 2.69–6.02]), ECG monitoring (2.67 [95% CI 1.82–3.95]), heart failure (OR 0.58 [95% CI 0.40–0.83]) and diabetes (OR 0.64 [95% CI 0.44–0.92]) were significantly associated with death(Figure 4).

## Discussion

This study elucidates characteristics and outcomes in patients with COVID-19 who develop IHCA. As of writing this report the pandemic is still surging worldwide with hundreds of thousands of new cases every day, despite successful vaccinations efforts. We show that the prevalence of COVID-19 among patients suffering an IHCA increased to approximately one in four cardiac arrests during the first pandemic wave, and one in five cardiac arrests during the second wave. Non-respiratory and non-infectious causes are dominating the cause of

1  
2  
3 cardiac arrest in COVID+ patients, and probability of survival at 30-days is halved by the  
4  
5  
6  
7 presence of COVID-19.  
8  
9

10 Regarding location of CA, we note that the most common location for COVID-19 patients  
11  
12  
13  
14 was regular wards, which are not monitored. This is unfortunate since our analyses showed  
15  
16  
17 that type of ward (monitored vs non-monitored) was significantly associated with survival,  
18  
19  
20 such that COVID+ cases in non-monitored wards displayed 74% lower probability of survival  
21  
22  
23 as compared with COVID+ cases in monitored wards. As compared with COVID- cases,  
24  
25  
26 cardiac arrest in the ER was more common in COVID+ cases. The often rapid deterioration of  
27  
28  
29 cardiopulmonary function in patients with COVID-19 may be one of the explanations for this  
30  
31  
32 finding. Fewer COVID+ cases were located in the CCU which is an expected finding due to  
33  
34  
35 the fact that cardiac etiology was less common among these patients.  
36  
37  
38  
39  
40

41 We note that the most common cause of cardiac arrest in COVID+ cases, as well as the most  
42  
43  
44 frequent clinical condition directly preceding the arrest, is respiratory. The high rate of  
45  
46  
47 respiratory etiology was driven by men (Supplementary Figure 6-7). A total of 57% of cases  
48  
49  
50 displayed hypoxia before cardiac arrest. This may highlight an opportunity for improving  
51  
52  
53 outcomes; measures to prevent hypoxia and to correct it immediately may reduce the risk of  
54  
55  
56 cardiac arrest in patients with COVID-19. On the other hand, it can be argued that we cannot  
57  
58  
59  
60

1  
2  
3 do that inference because we have not studied patients with and without hypoxia and followed  
4  
5  
6  
7 them in terms of risk of developing cardiac arrest (all our cases had already developed cardiac  
8  
9  
10 arrest). However, we know that COVID-19 causes ARDS (acute respiratory distress  
11  
12  
13 syndrome) and hypoxia, which can induce cardiac arrest.  
14  
15  
16  
17  
18  
19  
20

21 However, the fact that 43% of cases with COVID-19 did not have hypoxia prior to cardiac  
22  
23  
24 arrest suggests that other factors are important as well. Thromboembolism, myocardial  
25  
26  
27 infarction, arrhythmias, etc. may all contribute to the development of a cardiac arrest(12).  
28  
29  
30

31 A previous study from Wuhan showed that 87.5% of COVID+ cases with IHCA had a  
32  
33  
34 respiratory etiology and a study from Southwest Georgia that 53% of the patients with IHCA  
35  
36  
37 and COVID-19 had ARDS(5, 7). We report much lower rates of respiratory etiology (24%),  
38  
39  
40  
41 which may be due to several factors; e.g. in our study we had a total of 22 possible categories  
42  
43  
44 for cause of CA, as compared with two categories in the study from Wuhan. Also, patients in  
45  
46  
47 the study from Wuhan had severe COVID-19 and in our study population we do not know the  
48  
49  
50  
51 severity of the disease.  
52  
53  
54

55 The survival rates were poor among COVID+ patients with an overall 30-days survival of  
56  
57  
58 21%, compared to 36% among COVID-. The survival rate was, however, not as low as in the  
59  
60

1  
2  
3 study from Wuhan, in which 3% (151 patients studied) survived, or in the study from New  
4  
5  
6 York with 31 patients or in the study from Southwest Georgia with 63 patients with none  
7  
8  
9  
10 surviving (5, 7, 13). One reason for the poor survival could be the small number of patients  
11  
12  
13 found in a shockable rhythm (17% vs. 25% for COVID+ and COVID–, respectively) since  
14  
15  
16 patients with shockable rhythm have a more favorable outcome. After adjusting for sex, age  
17  
18  
19 and shockable rhythm the 30-day survival was though still significantly worse among patients  
20  
21  
22  
23 with an ongoing infection.  
24  
25

26  
27 We demonstrate that COVID+ women had halved chance of survival at 30 days, compared  
28  
29  
30 with COVID– women. We find it interesting that COVID+ women had acute MI three times  
31  
32  
33 as often as men, despite the fact that men exhibited shockable rhythm – and were defibrillated  
34  
35  
36 – twice as often as women; this cannot be explained by differences in prevalent heart failure,  
37  
38  
39 as there were none across men and women.  
40  
41  
42  
43

44 **Strengths and limitations.** This study includes all IHCA in Sweden which were reported to  
45  
46  
47 SRCR. The sample recorded in the SRCR is unbiased since all hospitals participate in the  
48  
49  
50 registry and all hospitals report data on COVID-19 status. However, we do not know the  
51  
52  
53 severity of the COVID-19 infection, and we do not know if COVID-19 was the main reason  
54  
55  
56 for admission to hospital. With regards to the classification of COVID-19 status, we have  
57  
58  
59  
60

1  
2  
3 performed a misclassification analysis which demonstrated that odds ratios were not  
4  
5  
6 materially affected by misclassification bias. Our study only includes IHCA's receiving CPR.  
7  
8  
9  
10 This leaves out all other patients with IHCA, e.g with a Do Not Attempt Resuscitation order.  
11  
12  
13  
14 It is important to stress the fact that our regression model that included only COVID-19 cases  
15  
16  
17 must be interpreted with caution due to the large number of predictors in the model, which  
18  
19  
20 had relatively few patients (resulting in wide confidence intervals). Further studies are  
21  
22  
23 warranted, using a larger study population, and a longer follow up especially regarding  
24  
25  
26 subgroup analyses, neurological outcomes and the quality of life for the patients. Information  
27  
28  
29 about the severity of COVID-19 and the reason for admission to the hospital would add  
30  
31  
32 valuable insights as well.  
33  
34  
35  
36  
37

### 38 **Conclusion**

39  
40  
41 During pandemic peaks, up to one fourth of all IHCA's are complicated by COVID-19, and  
42  
43  
44 these patients have halved chance of survival, with women displaying the worst outcomes.  
45  
46  
47  
48 The Pandemic has changed the whole world and the halved chance of survival displays just a  
49  
50  
51 little part of how it has affected us all.  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Funding

This work was supported by the Swedish Research Council [2019-02019] and the Swedish Heart and Lung Foundation [20200261].

**Conflict of interest:** none declared.

**Author Statement:** Astrid Holm and Araz Rawshani designed the study. Astrid Holm wrote the first draft of the manuscript, analyzed all data and made initial interpretations of data.

Araz Rawshani has been supervising. Matilda Jerkeman, Pedram Sultanian, Peter Lundgren, Annica Ravn-Fischer, Johan Israelsson, Jasna Giesecke and Johan Herlitz revised the article critically for important intellectual content and approved the version of the article to be published.

**Ethics statement:** The study was approved by the Swedish Ethical Review Authority (ID 2020-02017). The data was anonymized before the authors accessed it for the purpose of the study.

**Data sharing plan:** No additional data available

## References

1. Johns Hopkins University and Medicine COVID-19 map [internet] Johns Hopkins Coronavirus Resource Centre 2020. [updated 13/5/2021. Available from: <https://coronavirus.jhu.edu/map.html>.
2. Dödsorsaker första halvåret 2020. Socialstyrelsen. Hälsa- och sjukvård.; 2020 17/11/2020.
3. Andersson J. Samhällsspridning av coronaviruset i Sverige. Läkartidningen. 16/03/2020.
4. Hayek SS, Brenner SK, Azam TU, Shadid HR, Anderson E, Berlin H, et al. In-hospital cardiac arrest in critically ill patients with covid-19: multicenter cohort study. *Bmj*. 2020;371:m3513.
5. Shah P, Smith H, Olarewaju A, Jani Y, Cobb A, Owens J, et al. Is Cardiopulmonary Resuscitation Futile in Coronavirus Disease 2019 Patients Experiencing In-Hospital Cardiac Arrest? *Crit Care Med*. 2021;49(2):201-8.
6. Mitchell OJL, Yuriditsky E, Johnson NJ, Doran O, Buckler DG, Neefe S, et al. In-hospital cardiac arrest in patients with coronavirus 2019. *Resuscitation*. 2021;160:72-8.
7. Shao F, Xu S, Ma X, Xu Z, Lyu J, Ng M, et al. In-hospital cardiac arrest outcomes among patients with COVID-19 pneumonia in Wuhan, China. *Resuscitation*. 2020;151:18-23.
8. Sultanian P, Lundgren P, Strömsöe A, Aune S, Bergström G, Hagberg E, et al. Cardiac arrest in COVID-19: characteristics and outcomes of in- and out-of-hospital cardiac arrest. A report from the Swedish Registry for Cardiopulmonary Resuscitation. *European Heart Journal*. 2021.
9. Hessulf F, Herlitz J, Rawshani A, Aune S, Israelsson J, Södersved-Källestedt ML, et al. Adherence to guidelines is associated with improved survival following in-hospital cardiac arrest. *Resuscitation*. 2020;155:13-21.
10. Stef van Buuren, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations in R. *Journal of Statistical Software*. 2011;Vol 45.
11. 3.5 Classification and regression trees [Available from: <https://stefvanbuuren.name/fimd/sec-cart.html>.
12. Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary manifestations of COVID-19. *Nat Med*. 2020;26(7):1017-32.
13. Sheth V, Chishti I, Rothman A, Redlener M, Liang J, Pan D, et al. Outcomes of in-hospital cardiac arrest in patients with COVID-19 in New York City. *Resuscitation*. 2020;155:3-5.

**Table 1** Characteristics of 1613 patients with IHCA during the COVID-19 pandemic.

Variables	No infection COVID –	Ongoing infection COVID +	Unknown/NA UNA	SMD
<b>n</b>	1062	182	369	
<b>Demographics:</b>				
Age - mean (SD)	71.00 (13.32)	70.93 (12.43)	70.22 (13.60)	0.039
Woman - n (%)	388 (36.6)	68 (37.6)	151 (41.0)	0.061
<b>Location of cardiac arrest - n (%)</b>				
Coronary care unit - n (%)	155 (14.6)	14 ( 7.7)	50 (13.6)	
Intensive care unit - n (%)	77 ( 7.3)	25 (13.7)	19 ( 5.1)	
Operational room - n (%)	22 ( 2.1)	0 ( 0.0)	12 ( 3.3)	
Emergency room - n (%)	139 (13.1)	29 (15.9)	65 (17.6)	
Outpatient lab, radiology - n (%)	49 ( 4.6)	7 ( 3.8)	28 ( 7.6)	
Cathlab - n (%)	98 ( 9.2)	8 ( 4.4)	60 (16.3)	
Intermediate care unit - n (%)	25 ( 2.4)	15 ( 8.2)	10 ( 2.7)	
Regular ward - n (%)	468 (44.1)	82 (45.1)	116 (31.4)	
Other - n (%)	29 ( 2.7)	2 ( 1.1)	9 ( 2.4)	
<b>Critical times - median (IQR):</b>				
Time to alert – median (IQR)	1.00 [1.00, 1.00]	1.00 [1.00, 1.00]	1.00 [1.00, 1.00]	0.078
Time to CPR - median (IQR)	0.00 [0.00, 1.00]	0.00 [0.00, 0.00]	0.00 [0.00, 1.00]	0.109
Time to defibrillation - median (IQR)	2.00 [1.00, 5.00]	2.00 [1.00, 4.75]	1.00 [1.00, 4.00]	0.141
<b>Comorbidities - n (%):</b>				
MI, ongoing - n (%)	178 (23.6)	12 (12.0)	37 (29.4)	0.292
MI, previous - n (%)	163 (20.8)	13 (11.7)	26 (18.4)	0.165
Stroke, ongoing - n (%)	30 ( 3.8)	4 ( 3.7)	4 ( 3.0)	0.030
Stroke, previous - n (%)	82 (10.3)	7 ( 6.1)	15 (10.5)	0.105
Cancer, any - n (%)	165 (20.9)	20 (17.7)	28 (20.6)	0.054
Diabetes - n (%)	224 (27.9)	36 (31.0)	38 (27.0)	0.060
Heart failure - n (%)	229 (29.7)	36 (33.0)	36 (27.9)	0.074
Ejection fraction (%) - mean (SD)	46.14 (13.74)	46.44 (11.86)	44.94 (14.82)	0.073
EF <50% - n (%)	167 (46.0)	26 (48.1)	22 (46.8)	0.029
<b>Kidney function category - n (%)</b>				
eGFR <30 - n (%)	165 (21.6)	22 (20.0)	26 (20.0)	
eGFR 30–59- n (%)	216 (28.3)	32 (29.1)	44 (33.8)	
eGFR 60–89 - n (%)	198 (25.9)	25 (22.7)	30 (23.1)	
eGFR ≥90 - n (%)	185 (24.2)	31 (28.2)	30 (23.1)	
No kidney failure (eGFR ≥60) - n (%)	383 (50.1)	56 (50.9)	60 (46.2)	0.063
eGFR (ml/min/m2) - mean (SD)	66.89 (49.43)	71.26 (58.96)	63.78 (40.31)	0.099
<b>Cause of arrest: - n (%)</b>				
Hemorrhage - n (%)	34 (4.9)	2 (2.0)	10 (8.1)	
Myocardial infarction/ischemia- n (%)	181 (26.2)	15 (14.9)	41 (33.3)	



infarction/ischemi a	181 (26.2 )	15 (14.9 )	4 (33.3 )				
Other - n (%)	213 (30.8)	30 (29.7)	41 (33.3)				
Primary arrhythmia - n (%)	101 (14.6)	8 (7.9)	12 (9.8)				
Respiratory insufficiency - n (%)	73 (10.5)	24 (23.8)	7 (5.7)				
Sepsis/infection - n (%)	45 (6.5)	19 (18.8)	4 (3.3)				
Stroke/thromboembolism - n (%)	45 (6.5)	3 (3.0)	8 (6.5)				
<b>Early interventions - n (%):</b>							
Witnessed arrest - n (%)	857 (80.9)	140 (77.8)	306 (85.0)	0.124			
ECG monitoring - n (%)	635 (60.5)	89 (50.0)	221 (62.1)	0.163			
CPR before AGA - n (%)	845 (91.0)	146 (93.6)	268 (88.2)	0.127			
Defibrillated before AGA - n (%)	159 (17.9)	18 (11.9)	53 (19.0)	0.131			
Ventilated before AGA - n (%)	503 (63.2)	74 (54.8)	175 (69.2)	0.199			
Shockable rhythm - n (%)	247 (24.9)	29 (17.3)	90 (27.0)	0.158			
Defibrillated, any - n (%)	323 (31.5)	40 (22.7)	111 (32.8)	0.151			
Intubated - n (%)	473 (47.0)	100 (57.8)	177 (53.8)	0.145			
Adrenaline given - n (%)	668 (65.6)	125 (72.7)	223 (66.4)	0.102			
Antiarrhythmics - n (%)	139 (14.1)	17 (10.1)	48 (15.4)	0.107			
Mechanical compressions - n (%)	109 (10.8)	18 (10.4)	66 (20.0)	0.180			
Active temperature control - n (%)	54 (11.3)	5 (10.4)	3 (4.4)	0.173			
<b>Status at rescue team arrival - n (%):</b>							
Consciousness - n (%)	214 (23.1)	18 (11.7)	57 (19.3)	0.204			
Breathing - n (%)	288 (31.2)	30 (19.5)	84 (28.7)	0.181			
Pulse - n (%)	309 (33.8)	36 (23.4)	89 (30.4)	0.154			
<b>Follow-Up data - n (%):</b>							
Angiography - n (%)	115 (24.2)	8 (16.7)	15 (20.8)	0.124			
PCI - n (%)	87 (18.2)	4 (8.3)	16 (21.9)	0.258			
Pacemaker implanted - n (%)	80 (16.7)	2 (4.2)	4 (5.6)	0.281			
ICD implanted - n (%)	36 (7.5)	1 (2.1)	2 (2.8)	0.172			
ROSC - n (%)	520 (49.0)	64 (35.2)	142 (38.5)	0.188			
Death at 30 days - n (%)	666 (62.7)	141 (77.5)	237 (64.2)	0.218			
Death overall - n (%)	703 (66.2)	141 (77.5)	241 (65.3)	0.181			

1  
2  
3  
4 **SD = standard deviation; IQR = interquartile range; SMD = standardized mean difference (difference between**  
5 **the means for the two groups divided by their mutual standard deviation. Values below 0.1 (10%) are**  
6 **considered inconsequential (i.e., no significant difference between the groups)). CPR = Cardiopulmonary**  
7 **resuscitation, PCI = Percutaneous Coronary Intervention, ICD = implantable cardioverter-defibrillator. ROSC =**  
8 **return of spontaneous circulation. AGA= alarm group arrival**  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Figure Titles and Legends

### Figure 1: Characteristics of IHCA according to COVID-19 status

A: Monthly proportion of COVID-19 status among patients with IHCA, stratified on COVID-19 status. In March only cases after 15/03/2020 were included.

B: Etiology of IHCA, stratified on COVID-19 status. The y-axis shows percentages for each etiology in each group.

C: Clinical conditions 1 hour prior to IHCA, stratified on COVID-19 status. Only patients with data regarding the specific condition was included.

### Figure 2: Kaplan Meier survival curves

Kaplan Meier survival curves, separately for (A)Overall, (B)Women, (C)Men, (D)Age  $\geq 70$  year, (E)Age  $< 70$  year, (F)Cancer, (G)Heart failure, (H)Diabetes, (I)Kidney failure and (J)Myocardial infarction.  $p = \log$ -rank  $p$ -value. The numbers under the graphs are showing the survival in percentages. Regarding myocardial infarction acute MI is presented.

### Figure 3: Odds Ratio for 30-day survival


Forest plot with the adjusted odds ratio for 30-day survival among patients with ongoing infection vs. no infection and unknown/NA vs. no infection. Stratified on overall, men,

1  
2  
3 women, age < 70 years, age ≥ 70 years, heart failure, kidney failure, diabetes, myocardial  
4  
5  
6  
7 infarction and cancer. Myocardial infarction was defined as acute or previous MI.  
8  
9

#### 10 **Figure 4: Odds Ratio for 30-day survival**

11  
12  
13  
14 Forest plot with odds ratio for 30-day survival, stratified on the groups, no infection, ongoing  
15  
16  
17  
18 infection and overall, all in different colors. The 95% Confidence interval is shown between  
19  
20  
21 the bars. X-axis has a logarithmic scale. ECG=electrocardiogram, CA=cardiac arrest,  
22  
23  
24  
25 MI=myocardial infarction. CI=confidence interval.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Figure 1: Characteristics of IHCA according to COVID-19 status




**Figure 1A: Monthly proportion of COVID-19 status among patients with IHCA, stratified on COVID-19 status.** In March only cases after 15/03/2020 were included.

**Figure 1B: Etiology of IHCA, stratified on COVID-19 status.** The y-axis shows percentages for each etiology in each group.


**Figure 1C: Clinical conditions 1 hour prior to IHCA, stratified on COVID-19 status.** Only patients with data regarding the specific condition was included.

Figure 2: Kaplan Meier survival curves



**Figure 2: Kaplan Meier survival curves, separately for (A) Overall, (B) Women, (C) Men, (D) Age ≥70 year, (E) Age <70 year, (F) Cancer, (G) Heart failure, (H) Diabetes, (I) Kidney failure and (J) Myocardial infarction. p= log-rank p-value. The numbers under the graphs are showing the survival in percentages. Regarding myocardial infarction acute MI is**

Figure 3: Odds Ratio for 30-day survival



**Figure 3: Forest plot with the adjusted odds ratio for 30-day survival among patients with ongoing infection vs. no infection and unknown/NA vs. no infection.** Stratified on overall, men, women, age < 70 years, age ≥ 70 years, heart failure, kidney failure, diabetes, myocardial infarction and cancer. Myocardial infarction was defined as acute or previous MI.

Figure 4: Odds Ratio for 30-day survival




Figure 4: Forest plot with odds ratio for 30-day survival, stratified on the groups, no infection, ongoing infection and overall, all in different colors. The 95% Confidence interval is shown between the bars. X-axis has a logarithmic scale. ECG= electrocardiogram, CA= cardiac arrest, MI= myocardial infarction. CI= confidence interval.



1  
2  
3  
4 **Supplementary figures and tables**  
5

6  
7 **Characteristics and Outcomes in Patients**  
8 **with COVID-19 and In-Hospital Cardiac**  
9 **Arrest**  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Supplementary Table 1: Characteristics of COVID+ patients with IHCA in relation to sex.


**Supplementary Table 1:** Characteristics of 181 COVID+ patients with IHCA during the COVID-19 pandemic in relation to sex. One COVID+ patient had missing data on sex.

variables	Men	Women	SMD
<b>n</b>	113	68	
<b>Demographics:</b>			
Age - mean (SD)	71.39 (10.75)	70.35 (14.87)	0.080
<b>Location of cardiac arrest - n (%):</b>			0.249
Coronary care unit	7 ( 6.2)	7 ( 10.3)	
Intensive care unit	15 (13.3)	10 ( 14.7)	
Operational room	0 ( 0.0)	0 ( 0.0)	
Emergency room	17 (15.0)	11 ( 16.2)	
Outpatient lab, radiology	4 ( 3.5)	3 ( 4.4)	
Cathlab	6 ( 5.3)	2 ( 2.9)	
Intermediate care unit	11 ( 9.7)	4 ( 5.9)	
Regular ward	52 (46.0)	30 ( 44.1)	
Other	1 ( 0.9)	1 ( 1.5)	
<b>Critical times - median (IQR):</b>			
Time to alert – median (IQR)	1.00 [1.00, 1.00]	1.00 [1.00, 1.00]	0.256
Time to CPR - median (IQR)	0.00 [0.00, 0.00]	0.00 [0.00, 1.00]	0.031
Time to defibrillation - median	2.00 [1.00, 5.00]	2.00 [1.00, 2.00]	0.009
<b>Comorbidities - n (%):</b>			
MI, ongoing - n (%)	5 ( 7.6)	7 ( 21.2)	0.396
MI, previous - n (%)	11 (16.4)	2 ( 4.7)	0.391
Stroke, ongoing - n (%)	4 ( 5.8)	0 ( 0.0)	0.351
Stroke, previous - n (%)	5 ( 7.0)	2 ( 4.7)	0.102
Cancer, any - n (%)	13 (18.8)	6 ( 14.0)	0.132
Diabetes - n (%)	24 (33.3)	12 ( 27.9)	0.118
Heart failure - n (%)	23 (33.8)	13 ( 32.5)	0.028
Ejection fraction (%) - mean (SD)	44.84 (12.22)	49.31 (10.56)	0.392
EF <50% - n (%)	19 (51.4)	7 ( 43.8)	0.153
<b>Kidney function category - n (%):</b>			0.357
eGFR <30	16 (22.9)	6 ( 15.0)	
eGFR 30–59	17 (24.3)	15 ( 37.5)	
eGFR 60–89	18 (25.7)	7 ( 17.5)	
eGFR ≥90	19 (27.1)	12 ( 30.0)	
No kidney failure (eGFR ≥60)	37 (52.9)	19 ( 47.5)	0.107
eGFR (ml/min/m <sup>2</sup> ) - mean (SD)	72.72 (65.75)	68.70 (45.34)	0.071
<b>Cause of arrest - n (%):</b>			0.920
Hemorrhage	1 ( 1.5)	1 ( 2.9)	
Myocardial infarction/ischemia	7 (10.6)	8 ( 23.5)	
Other	18 (27.3)	12 ( 35.3)	
Primary arrhythmia	3 ( 4.5)	5 ( 14.7)	
Respiratory insufficiency	17 (25.8)	7 ( 20.6)	

Sepsis / infection	18 (27.3)	1 ( 2.9)	
Stroke / thromboembolism	2 ( 3.0)	0 ( 0.0)	
<b>Early interventions - n (%):</b>			
Witnessed arrest - n (%)	86 (76.8)	53 ( 79.1)	0.056
ECG monitoring - n (%)	56 (50.5)	33 ( 50.0)	0.009
CPR before AGA - n (%)	90 (92.8)	55 ( 94.8)	0.085
Defibrillated before AGA - n (%)	13 (13.8)	5 ( 8.9)	0.155
Ventilated before AGA- n (%)	49 (56.3)	25 ( 53.2)	0.063
Shockable rhythm - n (%)	22 (20.8)	7 ( 11.5)	0.254
Defibrillated, any - n (%)	29 (26.4)	11 ( 16.9)	0.231
Intubated - n (%)	61 (57.0)	38 ( 58.5)	0.029
Adrenaline given - n (%)	76 (70.4)	48 ( 76.2)	0.132
Antiarrhythmics - n (%)	11 (10.4)	6 ( 9.7)	0.023
Mechanical compressions - n (%)	12 (10.9)	5 ( 8.1)	0.097
Active temperature control - n (%)	2 (6.1)	3 ( 20.0)	0.423
<b>Status at rescue team arrival - n</b>			
Consciousness - n (%)	11 (11.3)	6 (10.7)	0.020
Breathing - n (%)	18 (18.6)	11 (19.6)	0.028
Pulse - n (%)	22 (22.7)	13 (23.2)	0.013
<b>Follow-Up data - n (%):</b>			
Angiography - n (%)	4 (12.1)	4 (26.7)	0.374
PCI - n (%)	2 (6.1)	2 (13.3)	0.248
Pacemaker implanted - n (%)	0 (0.0)	2 (13.3)	0.555
ICD implanted - n (%)	0 (0.0)	1 ( 6.7)	0.378
ROSC - n (%)	40 (35.4)	24 (35.3)	0.002
Death at 30 days - n (%)	85 (75.2)	56 (82.4)	0.175
Death overall - n (%)	85 (75.2)	56 (82.4)	0.175
Discharged alive - n (%)	16 (22.2)	6 (14.0)	0.216


**SD = standard deviation; IQR = interquartile range; SMD = standardized mean difference (difference between the means for the two groups divided by their mutual standard deviation. Values below 0.1 (10%) are considered inconsequential (i.e., no significant difference between the groups)). CPR = cardiopulmonary resuscitation, PCI = percutaneous coronary intervention, ICD = implantable cardioverter-defibrillator. ROSC = return of spontaneous circulation. AGA= alarm group arrival.**

Supplementary Figure 1: Missing data before and after imputation with MICE




**Supplementary Figure 1: Missing data before and after imputation with MICE.** A graphical view of the entire dataset is printed. Each column (variable) is depicted at the top and column color depicts type of variable. Each patient represents a row and white gaps indicate a missing data entry.

Supplementary Figure 2: Flow chart




**Supplementary Figure 2: Flow chart of the study population.** Patients who were less than 18 year of age, and cases occurring in the pre-pandemic period were excluded.

Supplementary Figure 3: Information on COVID-19 status during the study period.




**Supplementary Figure 3: Information on COVID-19 status during the study period.** No equals missing data, i.e. no information on COVID-19 status available. Yes equals, COVID +, COVID – or Unknown. In March only cases after 15/03/2020 were included.

Supplementary Figure 4: Distribution of age




Supplementary Figure 4: Distribution of age in relation to COVID-19 status.

Supplementary Figure 5: Etiology of IHCA, according to sex




Supplementary Figure 5A: Etiology of IHCA, men only.




Supplementary Figure 5B: Etiology of IHCA, women only.



## Supplementary Figure 6: Conditions preceding IHCA, according to sex




## Supplementary Figure 6A: Conditions preceding IHCA, men only.



## Supplementary Figure 6B: Conditions preceding IHCA, women only.

Supplementary Figure 7: Cox adjusted survival curve for the overall population



Supplementary Figure 7: Cox adjusted survival curve for the overall population, stratified on COVID-19 status.

## STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page No
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2-3
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	2
Objectives	3	State specific objectives, including any prespecified hypotheses	2
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	2
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	2
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	2
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	2
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5-6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5
Bias	9	Describe any efforts to address potential sources of bias	3-4
Study size	10	Explain how the study size was arrived at	5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5-6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6-7
		(b) Describe any methods used to examine subgroups and interactions	6-7
		(c) Explain how missing data were addressed	6-7
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	6-7
		(e) Describe any sensitivity analyses	6-7

Continued on next page

<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7
		(b) Give reasons for non-participation at each stage	7
		(c) Consider use of a flow diagram	Supplementary material
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	7-8
		(b) Indicate number of participants with missing data for each variable of interest	7-8
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	7
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	8-9
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	7-10
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Supplementary material
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	11
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	13-14
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11-14
Generalisability	21	Discuss the generalisability (external validity) of the study results	14
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	14

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

For peer review only

# BMJ Open

## A Cohort Study of the Characteristics and Outcomes in Patients with COVID-19 and In-Hospital Cardiac Arrest

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-054943.R2
Article Type:	Original research
Date Submitted by the Author:	08-Nov-2021
Complete List of Authors:	<p>Holm, Astrid; University of Gothenburg, Department of Molecular and Clinical Medicine            Jerkeman, Matilda; University of Gothenburg, Department of Molecular and Clinical Medicine            Sultanian, Pedram; University of Gothenburg, Department of Molecular and Clinical Medicine            Lundgren, Peter; University of Gothenburg, Department of Molecular and Clinical Medicine; Kalmar County Hospital, Department of Internal Medicine            Ravn-Fischer, Annica; University of Gothenburg, Department of Molecular and Clinical Medicine            Israelsson, Johan; Kalmar County Hospital, Department of Internal Medicine; Linnaeus University, Faculty of Health and Life Sciences            Giesecke, Jasna; Danderyd University Hospital            Herlitz, Johan; University of Borås, Centre for Prehospital Research            Rawshani, Araz; University of Gothenburg, Department of Molecular and Clinical Medicine</p>
<b>Primary Subject Heading</b>:	Cardiovascular medicine
Secondary Subject Heading:	Cardiovascular medicine, Infectious diseases
Keywords:	COVID-19, CARDIOLOGY, Adult cardiology < CARDIOLOGY, Coronary heart disease < CARDIOLOGY

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

# A Cohort Study of the Characteristics and Outcomes in Patients with COVID-19 and In-Hospital Cardiac Arrest

Astrid Holm, MD<sup>1</sup>, Matilda Jerkeman, MD<sup>1</sup>, Pedram Sultanian, MD<sup>1</sup>, Peter Lundgren, MD, PhD<sup>1,3,7</sup>, Annica Ravn-Fischer, MD, PhD, Docent<sup>1</sup>, Johan Israelsson, PhD<sup>3,4</sup>, Jasna Giesecke, RN<sup>5</sup>, Johan Herlitz, MD, PhD<sup>2,6</sup>, Araz Rawshani, MD, PhD<sup>1,2</sup>

## Affiliations:

<sup>1</sup>Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden

<sup>2</sup>The Swedish Registry for Cardiopulmonary Resuscitation, Centre of Registries, Västra Götaland County, Sweden

<sup>3</sup>Department of Internal Medicine, Division of Cardiology, Kalmar County Hospital, Region Kalmar County, Sweden

<sup>4</sup>Faculty of Health and Life Sciences, Linnaeus University, Kalmar, Sweden

<sup>5</sup>RN, Lead CPR coordinator, Clinicum- Centre for clinical skills, interprofessional education and advanced medical simulation, Danderyd University Hospital, Stockholm, Sweden

<sup>6</sup>Prehospiten – Centre for Prehospital Research, University of Borås, Borås, Sweden

<sup>7</sup>Region Västra Götaland, Sahlgrenska University Hospital, Department of Cardiology, Gothenburg, Sweden

## Contact information:

Astrid Holm

Email: [astrid.holm@gu.se](mailto:astrid.holm@gu.se)



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Phone: +358 400707722

**Manuscript word count:** 3052

## Abstract

**Objective:** We studied characteristics, survival, causes of cardiac arrest, conditions preceding cardiac arrest, predictors of survival, and trends in the prevalence of COVID-19 among in-hospital cardiac arrest (IHCA) cases.

**Design and setting:** Registry-based observational study.

**Participants:** We studied all cases ( $\geq 18$  years of age) of IHCA receiving cardiopulmonary resuscitation (CPR) in the Swedish Registry for Cardiopulmonary Resuscitation during 15/03/2020 to 31/12/2020. A total of 1613 patients were included and divided into the following groups: ongoing infection (**COVID+**; n=182), no infection (**COVID-**; n=1062) and unknown/not assessed (**UNA**; n=369).

**Main outcomes and measures:** We studied monthly trends in proportions of COVID-19 associated IHCAs, causes of IHCA in relation to COVID-19 status, clinical conditions preceding the cardiac arrest and predictors of survival.

**Results:** The rate of COVID+ patients suffering an IHCA increased to 23% during the first pandemic wave (April), then abated to 3% in July, and then increased to 19% during the second wave (December). Among COVID+ cases, 43% had respiratory insufficiency or

1  
2  
3 infection as the underlying cause of the cardiac arrest, compared to 18% among COVID–  
4  
5  
6 cases. The most common clinical sign preceding cardiac arrest was hypoxia (57%) among  
7  
8  
9 COVID+ cases. Odds ratio for 30-day survival for COVID+ cases was 0.50 (95% CI 0.33–  
10  
11  
12 0.76), compared with COVID– cases.  
13  
14  
15

16  
17 **Conclusion:** During pandemic peaks, up to one fourth of all IHCAs are complicated by  
18  
19 COVID-19, and these patients have halved chance of survival, with women displaying the  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

## Article Summary

### Strengths and limitations of this study

- This study includes all IHCAs in Sweden reported to the Swedish Registry for Cardiopulmonary Resuscitation. All hospitals throughout Sweden report IHCA cases to the registry.
- This study has detailed data regarding cardiac arrest parameters, including circumstances before arrest, resuscitation efforts, post-resuscitation care and survival. The study only includes cases in whom CPR attempts were deemed clinically justified.

- Despite the nationwide coverage of the registry, we identified only 182 COVID positive patients, and a large number of patients had unknown COVID status.

## Introduction

The COVID-19 pandemic has, as of Nov 6<sup>th</sup> 2021, infected over 249 million individuals and lead to the death of over 5 million individuals (1). COVID-19 is now the third leading cause of death in Sweden (2, 3). Multiple studies have demonstrated that in-hospital cardiac arrest (IHCA) among patients with COVID-19 is associated with poor survival (4-7). A recent study demonstrated that hypoxia was the main cause of cardiac arrest among 40% of patients with COVID-19 and IHCA (6).

We have previously reported on COVID-19 and IHCA in the Swedish Registry for Cardiopulmonary Resuscitation (SRCR), showing a 2.3-fold increase in 30-day mortality among cases with COVID-19, compared to pre-pandemic cases. This was mainly driven by a 9-fold increase in mortality among women with COVID-19. At the time, no case of IHCA with COVID-19 had been discharged alive (8). The current study expands our previous investigation, including more patients, longer follow-up and emphasizes on the causes of cardiac arrest, predictors of survival, coexisting conditions, and trends in the prevalence of COVID-19 among IHCA cases.

## Methods

### Data sources

This study is a registry-based observational study with data obtained from the SRCR during the time period 15/03/2020 to 31/12/2020. The SRCR is a national quality registry and has included IHCA cases since 2005. The data is collected by trained nurses who report patient data using a web-based protocol. The registry has previously been described in detail (9).

Vital status was obtained from the Swedish Population Registry and the last day of follow up was 31/12/2020.

### Study population

The study population included all patients  $\geq 18$  years of age suffering IHCA and receiving CPR throughout Sweden during the period 15/03/2020 to 31/12/2020. We used 15th of March as the start date of the pandemic as the Swedish Public Health Authority declared on March 16<sup>th</sup> 2020 that community spread had commenced (3). On 1<sup>st</sup> of April the SRCR started collecting data regarding COVID-19 status, and retrospectively identified 60 patients with COVID-19 who suffered IHCA during March (they were included in the study). Patients were divided into the following three groups: ongoing infection (COVID+; n=182), no infection (COVID-; n=1062) and unknown/not assessed (UNA; n=369). COVID+ was defined as patients registered with an ongoing COVID-19 infection, suspected ongoing infection or

1  
2  
3 patients with a recent infection (n=29). The UNA group was included in the study in order to  
4  
5  
6  
7 provide a complete picture of cases enrolled in the SRCR during the time period, and to  
8  
9  
10 evaluate whether missingness in COVID-19 status could entail selection bias.  
11  
12  
13

## 14 **Variable definitions**

15  
16 In SRCR a patient with cardiac arrest was defined as an unconscious patient with no or  
17  
18  
19  
20 abnormal breathing, in whom resuscitation or defibrillation was attempted. IHCA was defined  
21  
22  
23  
24 as cardiac arrest in patients admitted to the hospital.  
25  
26

27 With regards to previous coexisting conditions, heart failure was defined as any heart failure  
28  
29  
30 described before cardiac arrest. Kidney failure was defined as estimated glomerular filtration  
31  
32  
33  
34 rate (eGFR) below 60 ml/min/1.73 m<sup>2</sup>, calculated using the highest creatinine before cardiac  
35  
36  
37  
38 arrest with Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. The  
39  
40  
41 SRCR records data on the highest creatinine levels analyzed up to six months prior to CA.  
42  
43

44 Diabetes was defined as any diabetes diagnosis, regardless of type. Cancer was defined as any  
45  
46  
47 previously known cancer. Acute myocardial infarction (MI) was defined as an MI within 72  
48  
49  
50  
51 hours of CA. Previous myocardial infarction was defined as MI occurring earlier than 72  
52  
53  
54 hours preceding the CA.  
55  
56  
57  
58  
59  
60

1  
2  
3 Regarding clinical conditions one hour prior to CA, arrhythmia was defined as any  
4  
5  
6  
7 arrhythmia, hypoxia was defined as an oxygen saturation below 90%, hypotension was  
8  
9  
10 defined as systolic blood pressure below 90 mmHg, seizure was defined as any seizure with  
11  
12  
13 loss of consciousness, and heart failure was defined as any heart failure with pulmonary  
14  
15  
16 edema or severe shortness of breath with rales.

17  
18  
19  
20 Wards with monitoring included the coronary care unit (CCU), intensive care unit (ICU),  
21  
22  
23 operating room (OR), emergency room (ER), high dependency unit (HDU) or the  
24  
25  
26 catheterization laboratory.  
27  
28  
29

### 30 31 **Statistical analyses**

32  
33 Patient characteristics are reported in means and medians, along with standard deviations and  
34  
35  
36 interquartile ranges, respectively. The Kaplan-Meier estimator was used for describing  
37  
38  
39 survival distributions; the log rank test was used to test for differences in survival. Trends in  
40  
41  
42 rates of COVID-19 were assessed on a monthly basis during the entire study basis.  
43  
44  
45

46  
47 Logistic regression was used to calculate odds ratios for 30-days survival. These models  
48  
49  
50 assessed the association between COVID-19 status and 30-days survival, adjusting for age,  
51  
52  
53 sex and initial rhythm (shockable or non-shockable). We performed subgroup analyses in  
54  
55  
56 relation to sex, age and coexisting conditions (heart failure, cancer, diabetes, kidney failure  
57  
58  
59  
60

1  
2  
3 and myocardial infarction). These subgroup analyses served to clarify whether the association  
4  
5  
6  
7 between COVID status and survival was modified by age, sex or coexisting conditions.  
8  
9

10 In order to obtain estimates of overall survival, we used Cox proportional hazards model with  
11  
12  
13  
14 hours since CA as the time scale. The proportional hazards assumption was fulfilled for all  
15  
16  
17  
18 variables.  
19

20  
21 We used the MICE (Multiple Imputation By Chained Equations) algorithm to impute missing  
22  
23  
24  
25 values (10, 11) (Supplementary Figure 1). The imputed data set was used to calculate odds  
26  
27  
28 ratios for 30-days survival in the overall group, as well as in COVID+ and COVID- cases.  
29

30  
31 These models included age, sex, initial rhythm, time to start of cardiopulmonary resuscitation  
32  
33  
34 (CPR), time of CA, previous MI, type of ward, heart failure, ECG monitoring, diabetes and  
35  
36  
37  
38 acute MI.  
39

40  
41  
42 Analyses were done in R (v. 4.0.3, R Foundation for Statistical Computing) using RStudio.  
43  
44  
45

#### 46 **Patient and Public Involvement statement:**

  
47

48 No patients were involved.  
49  
50  
51  
52  
53

#### 54 **Results**

  
55

56 A total of 2,227 patients were enrolled in the SRCR between 01/01/2020 and 31/12/2020.  
57  
58  
59

60 After excluding patients <18 years (n=68) and pre-pandemic cases (n=546), 1,613 cases



1  
2  
3 remained from 15/03/2020 to 31/12/2020 and constituted the final study population

4  
5  
6  
7 (Supplementary Figure 2). There was a high rate of information on COVID-19 status during

8  
9  
10 the study period among patients registered in the registry (Supplementary Figure 3).

### 11 12 13 14 **Baseline characteristics**

15  
16 The overall mean age was 70.8 years, and the proportion of women was 37.6%. At the end of

17  
18  
19 follow-up, 341 (32.7%) patients were alive. The mean age was similar in the three groups:

20  
21  
22  
23 70.9 years in COVID+, 71.0 years in COVID– cases, and 70.2 years in cases with UNA

24  
25  
26 (Supplementary Figure 4). The proportion of women was also similar; 37.6% in COVID+ and

27  
28  
29  
30 36.6% in COVID– and 41.0% in UNA cases.

31  
32  
33 A regular ward was the most common place for cardiac arrest in all 3 groups; 45.1% of

34  
35  
36  
37 COVID+, 44.1% of COVID– and 31.4% of UNA cases occurred in regular wards (Table 1).

38  
39  
40 The emergency room (ER) was the second most common location for COVID+ cases

41  
42  
43  
44 (15.9%).

45  
46  
47 Regarding comorbidities, acute myocardial infarction was observed in 12.0% of COVID+ and

48  
49  
50  
51 23.6% of COVID– cases. Previous myocardial infarction was observed in 11.7% of COVID+,

52  
53  
54  
55 20.8% of COVID– and 11.7% of UNA cases. The prevalence of heart failure, cancer and

56  
57  
58  
59  
60 diabetes was similar across all groups (Table 1).

1  
2  
3 Fewer cases among COVID+ individuals had a shockable rhythm (17.3%), compared with  
4  
5  
6 COVID- (24.9%) cases. Likewise, fewer cases among COVID+ (22.7%) were defibrillated,  
7  
8  
9  
10 compared with COVID- cases (31.5%). COVID+ cases were ventilated in 54.8% of cases  
11  
12  
13 before rescue team arrival, as compared with 63.2% in COVID- cases.  
14  
15

### 16 17 **Follow-up**

18  
19 Return of spontaneous circulation (ROSC) after initial resuscitation, was less common in  
20  
21  
22 COVID+ cases, as compared with COVID- cases. Also, angiography, PCI, pacemaker and  
23  
24  
25 ICD implantation post cardiac arrest were less common in COVID+ cases.  
26  
27  
28  
29  
30  
31  
32  
33  
34

### 35 **Sex specific characteristics**

36  
37 Acute myocardial infarction was observed in 21.2% of COVID+ women and 7.6% of  
38  
39  
40 COVID+ men. Previous myocardial infarction was observed in 4.7% of COVID+ women and  
41  
42  
43 16.2% of COVID+ men. The prevalence of previous stroke, renal failure, heart failure, cancer  
44  
45  
46 and diabetes were similar among men and women, as was location at the time of cardiac  
47  
48  
49 arrest. COVID+ men were more likely to have a shockable rhythm (20.8%) compared with  
50  
51  
52 COVID+ women (11.5%), and to be defibrillated (26.4% in men vs. 16.9% in women)  
53  
54  
55  
56  
57 (Supplementary Table 1).  
58  
59  
60

## Monthly trends in COVID-19 associated IHCA

In March, April and May 14%, 23% and 20% of patients suffering IHCA were COVID+ (data from 16<sup>th</sup> March). The proportion of COVID+ cases diminished rapidly during June to July. From September onwards the COVID+ cases increased again to reach 19% in December. In Figure 1A additional details regarding monthly variations are presented.

## Etiology of IHCA

The most common cause of IHCA among COVID+ cases was respiratory insufficiency (24%, n=24), and the second most common cause was sepsis or other infection (19%, n=19).

Respiratory insufficiency and sepsis/other infection were less common in the other groups (Figure 1B), which instead displayed higher rates of acute myocardial infarction.

## Clinical conditions one hour prior to IHCA

As evident in Figure 1C, which describes the clinical conditions preceding (up to 60 minutes) the cardiac arrest, hypoxia was more common among COVID+ cases (57%), as compared with COVID- cases (34%).

## Survival analysis

The Kaplan Meier plots (Figure 2) show that COVID+ cases generally had a lower probability of survival compared to both COVID- and UNA cases. The overall 30-day survival (Figure 2A) was 21% among COVID+, compared with 36% in COVID- cases

1  
2  
3 (p=0.00086). The subgroup analysis of women (Figure 2B) showed low survival rates in  
4  
5  
6 COVID+ cases (16% 30-day survival). The subgroup analysis of men (Figure 2C) showed  
7  
8  
9 low survival rates in COVID+ cases (23% 30-day survival). The 30 days survival among  
10  
11  
12 COVID+ aged >70 years was 18% (Figure 2D), as compared with 25% of COVID+ cases  
13  
14  
15 aged 70 years or younger (Figure 2E). Survival curves for the subgroups of individuals with  
16  
17  
18 cancer, heart failure and diabetes, did not display any distinct patterns (Figure 2F-2H), with  
19  
20  
21 all p values >0.1. Patients with kidney failure had a 30 days survival of 13% among COVID+  
22  
23  
24 cases (Figure 2I). Patients with acute MI had a 30 days survival of 8% among COVID+ cases  
25  
26  
27  
28  
29 (Figure 2J).

30  
31  
32  
33  
34 Cox adjusted survival curves are presented in Supplementary Figure 5; COVID+ cases  
35  
36  
37 displayed the lowest probability of survival, whereas there was no material difference  
38  
39  
40  
41 between COVID- and UNA cases.

### 42 43 44 **Odds ratios for 30-days survival**

45  
46  
47 When adjusted for age, sex and initial rhythm the odds ratios for 30-day survival, comparing  
48  
49  
50 COVID+ vs. COVID-, were 0.50 (0.33-0.76) overall, 0.53 (0.31-0.88) for men, and 0.44  
51  
52  
53 (0.20-0.88) for women. In the subgroup of patients with heart failure, myocardial infarction  
54  
55  
56 and cancer, we found no statistically significant associations, whereas in the subgroup of  
57  
58  
59  
60

1  
2  
3 COVID+ patients with kidney failure, odds ratio for 30-days survival was 0.43 (0.16–0.99),  
4  
5  
6  
7 when compared with COVID– cases (Figure 3).  
8  
9

## 10 11 Predictors of survival

12  
13 Regarding predictors of 30-days survival among COVID+ we note that confidence intervals  
14  
15  
16 were generally wide. Lack of ECG monitoring and delayed start of CPR showed point  
17  
18  
19 estimates below 1.0, although non-significant. Odds ratio for patients treated in non-  
20  
21  
22 monitored wards was 0.26 (95% CI 0.08-0.78) as compared with monitored wards (Figure 4).  
23  
24  
25  
26  
27 No coexisting condition was associated with survival among COVID+ cases.  
28  
29

30  
31 Among COVID– cases, the factors that were significantly associated with 30-days survival  
32  
33  
34 were shockable rhythm (OR 4.18 [95% CI 2.69–6.02]), ECG monitoring (2.67 [95% CI 1.82–  
35  
36  
37 3.95]), heart failure (OR 0.58 [95% CI 0.40–0.83]) and diabetes (OR 0.64 [95% CI 0.44–  
38  
39  
40  
41 0.92]; Figure 4).  
42  
43  
44  
45

## 46 47 Discussion

48  
49 This study elucidates characteristics and outcomes in patients with COVID-19 who develop  
50  
51  
52 IHCA. We show that the prevalence of COVID-19 among patients suffering an IHCA  
53  
54  
55 increased to approximately one in four cardiac arrests during the first pandemic wave, and  
56  
57  
58  
59  
60

1  
2  
3 one in five cardiac arrests during the second wave. In IHCA the probability of survival to 30-  
4  
5  
6  
7 days is halved by the presence of COVID-19.  
8  
9

10 Regarding location of CA, we note that the most common location for COVID+ patients was  
11  
12  
13  
14 regular wards, which are not monitored. This is unfortunate since our analyses showed that  
15  
16  
17 type of ward (monitored vs non-monitored) was significantly associated with survival, such  
18  
19  
20 that COVID+ cases in non-monitored wards displayed 74% lower probability of survival as  
21  
22  
23 compared with COVID+ cases in monitored wards. As compared with COVID- cases,  
24  
25  
26  
27 cardiac arrest in the ER was more common in COVID+ cases. The often rapid deterioration of  
28  
29  
30 cardiopulmonary function in patients with COVID-19 may be one of the explanations for this  
31  
32  
33 finding. Fewer COVID+ cases were located in the CCU, which was an expected finding given  
34  
35  
36  
37 that cardiac etiology was less common among these patients.  
38  
39  
40

41 We note that the most common cause of cardiac arrest in COVID+ cases, as well as the most  
42  
43  
44 frequent clinical condition directly preceding the arrest, was respiratory. A total of 57% of  
45  
46  
47 cases displayed hypoxia before cardiac arrest. This may highlight an opportunity for  
48  
49  
50 improving outcomes; measures to prevent hypoxia and to correct it immediately may reduce  
51  
52  
53 the risk of cardiac arrest in patients with COVID-19. The high rate of respiratory etiology was  
54  
55  
56  
57 driven by men (Supplementary Figure 6-7).  
58  
59  
60

1  
2  
3 However, the fact that 43% of cases with COVID-19 did not have hypoxia prior to cardiac  
4  
5  
6  
7 arrest suggests that other factors are important as well. Thromboembolism, myocardial  
8  
9  
10 infarction, arrhythmias, etc. may all contribute to the development of a cardiac arrest (12).  
11  
12  
13

14 A previous study from Wuhan showed that 87.5% of COVID+ cases with IHCA had a  
15  
16  
17 respiratory etiology and a study from Southwest Georgia that 53% of the patients with IHCA  
18  
19  
20 and COVID-19 had ARDS (5, 7).  
21  
22  
23

24 The survival rates were poor among COVID+ patients with an overall 30-days survival of  
25  
26  
27 21%, compared to 36% among COVID-. The survival rate was, however, not as low as in the  
28  
29  
30 study from Wuhan, in which 3% (151 patients studied) survived, or in the study from New  
31  
32  
33 York with 31 patients or in the study from Southwest Georgia with 63 patients with none  
34  
35  
36 surviving (5, 7, 13). One reason for the poor survival could be the small number of patients  
37  
38  
39 found in shockable rhythm (17% vs. 25% for COVID+ and COVID-, respectively) since  
40  
41  
42 patients with shockable rhythm have a more favorable outcome. After adjusting for sex, age  
43  
44  
45 and shockable rhythm the 30-day survival was still significantly worse among patients with  
46  
47  
48 an ongoing infection.  
49  
50  
51  
52  
53

54 We demonstrate that COVID+ women had halved chance of survival at 30 days, compared  
55  
56  
57 with COVID- women. We find it interesting that COVID+ women had acute MI three times  
58  
59  
60

1  
2  
3 as often as men, despite the fact that men exhibited shockable rhythm – and were defibrillated  
4  
5  
6  
7 – twice as often as women.  
8  
9

10 **Strengths and limitations.** This study includes all IHCA in Sweden which were reported to  
11  
12 SRCR. The sample recorded in the SRCR is unbiased since all hospitals participate in the  
13  
14 registry and all hospitals report data on COVID-19 status. However, we do not know the  
15  
16 severity of the COVID-19 infection, and we do not know if COVID-19 was the main reason  
17  
18 for admission to hospital. With regards to the classification of COVID-19 status, we have  
19  
20 performed a misclassification analysis which demonstrated that odds ratios were not  
21  
22 materially affected by misclassification bias. Missingness was prevalent with regards to cause  
23  
24 of cardiac arrest, which is due to the difficulties determining this factor. However, we find no  
25  
26 reason to believe that missingness differs across COVID status categories, and it should  
27  
28 therefore not bias our inferences. Our study only includes IHCA receiving CPR. This leaves  
29  
30 out all other patients with IHCA, e.g with a Do Not Attempt Resuscitation order.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48 Our regression models that included only COVID-19 cases should be interpreted with caution  
49  
50 due to the large number of predictors in the model, with relatively few patients (resulting in  
51  
52 wide confidence intervals). Further studies are warranted, using a larger study population, and  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 a longer follow up especially regarding subgroup analyses, neurological outcomes and the  
4  
5  
6  
7 quality of life for these patients.  
8  
9

## 10 **Conclusion**

11  
12  
13  
14 During pandemic peaks, up to one fourth of all IHCA's are complicated by COVID-19, and  
15  
16  
17 these patients have halved chance of survival, with women displaying the worst outcomes.  
18  
19  
20  
21  
22

## 23 **Funding**

24  
25  
26  
27 This work was supported by the Swedish Research Council [2019-02019] and the Swedish  
28  
29  
30 Heart and Lung Foundation [20200261].  
31  
32  
33  
34

35 **Conflict of interest:** none declared.  
36  
37  
38

39 **Author Statement:** Astrid Holm and Araz Rawshani designed the study. Astrid Holm wrote  
40  
41  
42 the first draft of the manuscript, analyzed all data and made initial interpretations of data.  
43  
44  
45

46 Araz Rawshani has been supervising. Matilda Jerkeman, Pedram Sultanian, Peter Lundgren,  
47  
48  
49 Annica Ravn-Fischer, Johan Israelsson, Jasna Giesecke and Johan Herlitz revised the article  
50  
51  
52 critically for important intellectual content and approved the version of the article to be  
53  
54  
55  
56 published.  
57  
58  
59  
60

**Ethics statement:** The study was approved by the Swedish Ethical Review Authority (ID

2020-02017). The data was anonymized before the authors accessed it for the purpose of the study.

**Data sharing plan:** No additional data available

## References

1. Johns Hopkins University and Medicine COVID-19 map [internet] Johns Hopkins Coronavirus Resource Centre 2020. [updated 13/5/2021. Available from: <https://coronavirus.jhu.edu/map.html>.
2. Dödsorsaker första halvåret 2020. Socialstyrelsen. Hälsa- och sjukvård.; 2020 17/11/2020.
3. Andersson J. Samhällsspridning av coronaviruset i Sverige. Läkartidningen. 16/03/2020.
4. Hayek SS, Brenner SK, Azam TU, Shadid HR, Anderson E, Berlin H, et al. In-hospital cardiac arrest in critically ill patients with covid-19: multicenter cohort study. *Bmj*. 2020;371:m3513.
5. Shah P, Smith H, Olarewaju A, Jani Y, Cobb A, Owens J, et al. Is Cardiopulmonary Resuscitation Futile in Coronavirus Disease 2019 Patients Experiencing In-Hospital Cardiac Arrest? *Crit Care Med*. 2021;49(2):201-8.
6. Mitchell OJL, Yuriditsky E, Johnson NJ, Doran O, Buckler DG, Neefe S, et al. In-hospital cardiac arrest in patients with coronavirus 2019. *Resuscitation*. 2021;160:72-8.
7. Shao F, Xu S, Ma X, Xu Z, Lyu J, Ng M, et al. In-hospital cardiac arrest outcomes among patients with COVID-19 pneumonia in Wuhan, China. *Resuscitation*. 2020;151:18-23.
8. Sultanian P, Lundgren P, Strömsöe A, Aune S, Bergström G, Hagberg E, et al. Cardiac arrest in COVID-19: characteristics and outcomes of in- and out-of-hospital cardiac arrest. A report from the Swedish Registry for Cardiopulmonary Resuscitation. *European Heart Journal*. 2021.
9. Hessulf F, Herlitz J, Rawshani A, Aune S, Israelsson J, Södersved-Källestedt ML, et al. Adherence to guidelines is associated with improved survival following in-hospital cardiac arrest. *Resuscitation*. 2020;155:13-21.
10. Stef van Buuren, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations in R. *Journal of Statistical Software*. 2011;Vol 45.
11. 3.5 Classification and regression trees [Available from: <https://stefvanbuuren.name/fimd/sec-cart.html>.
12. Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary manifestations of COVID-19. *Nat Med*. 2020;26(7):1017-32.
13. Sheth V, Chishti I, Rothman A, Redlener M, Liang J, Pan D, et al. Outcomes of in-hospital cardiac arrest in patients with COVID-19 in New York City. *Resuscitation*. 2020;155:3-5.

**Table 1** Characteristics of 1613 patients with IHCA during the COVID-19 pandemic.

Variables	No infection COVID –	Ongoing infection COVID +	Unknown/NA UNA	SMD
<b>n</b>	1062	182	369	
<b>Demographics:</b>				
Age - mean (SD)	71.00 (13.32)	70.93 (12.43)	70.22 (13.60)	0.039
Woman - n (%)	388 (36.6)	68 (37.6)	151 (41.0)	0.061
<b>Location of cardiac arrest - n (%)</b>				0.527
Coronary care unit - n (%)	155 (14.6)	14 ( 7.7)	50 (13.6)	
Intensive care unit - n (%)	77 ( 7.3)	25 (13.7)	19 ( 5.1)	
Operational room - n (%)	22 ( 2.1)	0 ( 0.0)	12 ( 3.3)	
Emergency room - n (%)	139 (13.1)	29 (15.9)	65 (17.6)	
Outpatient lab, radiology - n (%)	49 ( 4.6)	7 ( 3.8)	28 ( 7.6)	
Cathlab - n (%)	98 ( 9.2)	8 ( 4.4)	60 (16.3)	
Intermediate care unit - n (%)	25 ( 2.4)	15 ( 8.2)	10 ( 2.7)	
Regular ward - n (%)	468 (44.1)	82 (45.1)	116 (31.4)	
Other - n (%)	29 ( 2.7)	2 ( 1.1)	9 ( 2.4)	
<b>Critical times - median (IQR):</b>				
Time to alert – median (IQR)	1.00 [1.00, 1.00]	1.00 [1.00, 1.00]	1.00 [1.00, 1.00]	0.078
Time to CPR - median (IQR)	0.00 [0.00, 1.00]	0.00 [0.00, 0.00]	0.00 [0.00, 1.00]	0.109
Time to defibrillation - median (IQR)	2.00 [1.00, 5.00]	2.00 [1.00, 4.75]	1.00 [1.00, 4.00]	0.141
<b>Comorbidities - n (%):</b>				
MI, ongoing - n (%)	178 (23.6)	12 (12.0)	37 (29.4)	0.292
MI, previous - n (%)	163 (20.8)	13 (11.7)	26 (18.4)	0.165
Stroke, ongoing - n (%)	30 ( 3.8)	4 ( 3.7)	4 ( 3.0)	0.030
Stroke, previous - n (%)	82 (10.3)	7 ( 6.1)	15 (10.5)	0.105
Cancer, any - n (%)	165 (20.9)	20 (17.7)	28 (20.6)	0.054
Diabetes - n (%)	224 (27.9)	36 (31.0)	38 (27.0)	0.060
Heart failure - n (%)	229 (29.7)	36 (33.0)	36 (27.9)	0.074
Ejection fraction (%) - mean (SD)	46.14 (13.74)	46.44 (11.86)	44.94 (14.82)	0.073
EF <50% - n (%)	167 (46.0)	26 (48.1)	22 (46.8)	0.029
<b>Kidney function category - n (%)</b>				0.121
eGFR <30 - n (%)	165 (21.6)	22 (20.0)	26 (20.0)	
eGFR 30–59 - n (%)	216 (28.3)	32 (29.1)	44 (33.8)	
eGFR 60–89 - n (%)	198 (25.9)	25 (22.7)	30 (23.1)	
eGFR ≥90 - n (%)	185 (24.2)	31 (28.2)	30 (23.1)	
No kidney failure (eGFR ≥60) - n (%)	383 (50.1)	56 (50.9)	60 (46.2)	0.063
eGFR (ml/min/m <sup>2</sup> ) - mean (SD)	66.89 (49.43)	71.26 (58.96)	63.78 (40.31)	0.099
<b>Cause of arrest: - n (%)</b>				0.629
Hemorrhage - n (%)	34 (4.9)	2 (2.0)	10 (8.1)	
Myocardial infarction/ischemia - n (%)	181 (26.2)	15 (14.9)	41 (33.3)	

infarction/ischemi a	181 (26.2 )	15 (14.9 )	4 (33.3 )				
Other - n (%)	213 (30.8)	30 (29.7)	41 (33.3)				
Primary arrhythmia - n (%)	101 (14.6)	8 (7.9)	12 (9.8)				
Respiratory insufficiency - n (%)	73 (10.5)	24 (23.8)	7 (5.7)				
Sepsis/infection - n (%)	45 (6.5)	19 (18.8)	4 (3.3)				
Stroke/thromboembolism - n (%)	45 (6.5)	3 (3.0)	8 (6.5)				
<b>Early interventions - n (%):</b>							
Witnessed arrest - n (%)	857 (80.9)	140 (77.8)	306 (85.0)	0.124			
ECG monitoring - n (%)	635 (60.5)	89 (50.0)	221 (62.1)	0.163			
CPR before AGA - n (%)	845 (91.0)	146 (93.6)	268 (88.2)	0.127			
Defibrillated before AGA - n (%)	159 (17.9)	18 (11.9)	53 (19.0)	0.131			
Ventilated before AGA - n (%)	503 (63.2)	74 (54.8)	175 (69.2)	0.199			
Shockable rhythm - n (%)	247 (24.9)	29 (17.3)	90 (27.0)	0.158			
Defibrillated, any - n (%)	323 (31.5)	40 (22.7)	111 (32.8)	0.151			
Intubated - n (%)	473 (47.0)	100 (57.8)	177 (53.8)	0.145			
Adrenaline given - n (%)	668 (65.6)	125 (72.7)	223 (66.4)	0.102			
Antiarrhythmics - n (%)	139 (14.1)	17 (10.1)	48 (15.4)	0.107			
Mechanical compressions - n (%)	109 (10.8)	18 (10.4)	66 (20.0)	0.180			
Active temperature control - n (%)	54 (11.3)	5 (10.4)	3 (4.4)	0.173			
<b>Status at rescue team arrival - n (%):</b>							
Consciousness - n (%)	214 (23.1)	18 (11.7)	57 (19.3)	0.204			
Breathing - n (%)	288 (31.2)	30 (19.5)	84 (28.7)	0.181			
Pulse - n (%)	309 (33.8)	36 (23.4)	89 (30.4)	0.154			
<b>Follow-Up data - n (%):</b>							
Angiography - n (%)	115 (24.2)	8 (16.7)	15 (20.8)	0.124			
PCI - n (%)	87 (18.2)	4 (8.3)	16 (21.9)	0.258			
Pacemaker implanted - n (%)	80 (16.7)	2 (4.2)	4 (5.6)	0.281			
ICD implanted - n (%)	36 (7.5)	1 (2.1)	2 (2.8)	0.172			
ROSC - n (%)	520 (49.0)	64 (35.2)	142 (38.5)	0.188			
Death at 30 days - n (%)	666 (62.7)	141 (77.5)	237 (64.2)	0.218			
Death overall - n (%)	703 (66.2)	141 (77.5)	241 (65.3)	0.181			

1  
2  
3  
4 **SD = standard deviation; IQR = interquartile range; SMD = standardized mean difference (difference between**  
5 **the means for the two groups divided by their mutual standard deviation. Values below 0.1 (10%) are**  
6 **considered inconsequential (i.e., no significant difference between the groups)). CPR = Cardiopulmonary**  
7 **resuscitation, PCI = Percutaneous Coronary Intervention, ICD = implantable cardioverter-defibrillator. ROSC =**  
8 **return of spontaneous circulation. AGA= alarm group arrival**  
9

## Figure Titles and Legends

### Figure 1: Characteristics of IHCA according to COVID-19 status

25  
26  
27  
28  
29  
30  
31  
32 A: Monthly proportion of COVID-19 status among patients with IHCA, stratified on COVID-  
33  
34  
35 19 status. In March only cases after 15/03/2020 were included.

36  
37  
38  
39 B: Etiology of IHCA, stratified on COVID-19 status. The y-axis shows percentages for each  
40  
41  
42 etiology in each group.

43  
44  
45  
46 C: Clinical conditions 1 hour prior to IHCA, stratified on COVID-19 status. Only patients  
47  
48  
49 with data regarding the specific condition was included.

### Figure 2: Kaplan Meier survival curves

1  
2  
3 Kaplan Meier survival curves, separately for (A)Overall, (B)Women, (C)Men, (D)Age  $\geq 70$   
4  
5  
6  
7 year, (E)Age  $< 70$  year, (F)Cancer, (G)Heart failure, (H)Diabetes, (I)Kidney failure and  
8  
9  
10 (J)Myocardial infarction.  $p = \log$ -rank  $p$ -value. The numbers under the graphs are showing the  
11  
12  
13 survival in percentages. Regarding myocardial infarction acute MI is presented.  
14  
15  
16


### 17 **Figure 3: Odds Ratio for 30-day survival**

18  
19  
20  
21 Forest plot with the adjusted odds ratio for 30-day survival among patients with ongoing  
22  
23  
24 infection vs. no infection and unknown/NA vs. no infection. Stratified on overall, men,  
25  
26  
27 women, age  $< 70$  years, age  $\geq 70$  years, heart failure, kidney failure, diabetes, myocardial  
28  
29  
30 infarction and cancer. Myocardial infarction was defined as acute or previous MI.  
31  
32  
33  
34

### 35 **Figure 4: Odds Ratio for 30-day survival**

36  
37  
38  
39 Forest plot with odds ratio for 30-day survival, stratified on the groups, no infection, ongoing  
40  
41  
42 infection and overall, all in different colors. The 95% Confidence interval is shown between  
43  
44  
45 the bars. X-axis has a logarithmic scale. ECG=electrocardiogram, CA=cardiac arrest,  
46  
47  
48  
49 MI=myocardial infarction. CI=confidence interval.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Figure 1: Characteristics of IHCA according to COVID-19 status




**Figure 1A: Monthly proportion of COVID-19 status among patients with IHCA, stratified on COVID-19 status.** In March only cases after 15/03/2020 were included.

**Figure 1B: Etiology of IHCA, stratified on COVID-19 status.** The y-axis shows percentages for each etiology in each group.

**Figure 1C: Clinical conditions 1 hour prior to IHCA, stratified on COVID-19 status.** Only patients with data regarding the specific condition was included.


Figure 2: Kaplan Meier survival curves



**Figure 2: Kaplan Meier survival curves, separately for (A) Overall, (B) Women, (C) Men, (D) Age ≥70 year, (E) Age <70 year, (F) Cancer, (G) Heart failure, (H) Diabetes, (I) Kidney failure and (J) Myocardial infarction. p= log-rank p-value. The numbers under the graphs are showing the survival in percentages. Regarding myocardial infarction acute MI is**



Figure 3: Odds Ratio for 30-day survival



**Figure 3: Forest plot with the adjusted odds ratio for 30-day survival among patients with ongoing infection vs. no infection and unknown/NA vs. no infection.** Stratified on overall, men, women, age < 70 years, age ≥ 70 years, heart failure, kidney failure, diabetes, myocardial infarction and cancer. Myocardial infarction was defined as acute or previous MI.

Figure 4: Odds Ratio for 30-day survival



Figure 4: Forest plot with odds ratio for 30-day survival, stratified on the groups, no infection, ongoing infection and overall, all in different colors. The 95% Confidence interval is shown between the bars. X-axis has a logarithmic scale. ECG= electrocardiogram, CA= cardiac arrest, MI= myocardial infarction. CI= confidence interval.

1  
2  
3  
4 **Supplementary figures and tables**  
5

6  
7 **Characteristics and Outcomes in Patients**  
8 **with COVID-19 and In-Hospital Cardiac**  
9 **Arrest**  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Supplementary Table 1: Characteristics of COVID+ patients with IHCA in relation to sex.


**Supplementary Table 1:** Characteristics of 181 COVID+ patients with IHCA during the COVID-19 pandemic in relation to sex. One COVID+ patient had missing data on sex.

variables	Men	Women	SMD
<b>n</b>	113	68	
<b>Demographics:</b>			
Age - mean (SD)	71.39 (10.75)	70.35 (14.87)	0.080
<b>Location of cardiac arrest - n (%):</b>			0.249
Coronary care unit	7 ( 6.2)	7 ( 10.3)	
Intensive care unit	15 (13.3)	10 ( 14.7)	
Operational room	0 ( 0.0)	0 ( 0.0)	
Emergency room	17 (15.0)	11 ( 16.2)	
Outpatient lab, radiology	4 ( 3.5)	3 ( 4.4)	
Cathlab	6 ( 5.3)	2 ( 2.9)	
Intermediate care unit	11 ( 9.7)	4 ( 5.9)	
Regular ward	52 (46.0)	30 ( 44.1)	
Other	1 ( 0.9)	1 ( 1.5)	
<b>Critical times - median (IQR):</b>			
Time to alert – median (IQR)	1.00 [1.00, 1.00]	1.00 [1.00, 1.00]	0.256
Time to CPR - median (IQR)	0.00 [0.00, 0.00]	0.00 [0.00, 1.00]	0.031
Time to defibrillation - median	2.00 [1.00, 5.00]	2.00 [1.00, 2.00]	0.009
<b>Comorbidities - n (%):</b>			
MI, ongoing - n (%)	5 ( 7.6)	7 ( 21.2)	0.396
MI, previous - n (%)	11 (16.4)	2 ( 4.7)	0.391
Stroke, ongoing - n (%)	4 ( 5.8)	0 ( 0.0)	0.351
Stroke, previous - n (%)	5 ( 7.0)	2 ( 4.7)	0.102
Cancer, any - n (%)	13 (18.8)	6 ( 14.0)	0.132
Diabetes - n (%)	24 (33.3)	12 ( 27.9)	0.118
Heart failure - n (%)	23 (33.8)	13 ( 32.5)	0.028
Ejection fraction (%) - mean (SD)	44.84 (12.22)	49.31 (10.56)	0.392
EF <50% - n (%)	19 (51.4)	7 ( 43.8)	0.153
<b>Kidney function category - n (%):</b>			0.357
eGFR <30	16 (22.9)	6 ( 15.0)	
eGFR 30–59	17 (24.3)	15 ( 37.5)	
eGFR 60–89	18 (25.7)	7 ( 17.5)	
eGFR ≥90	19 (27.1)	12 ( 30.0)	
No kidney failure (eGFR ≥60)	37 (52.9)	19 ( 47.5)	0.107
eGFR (ml/min/m <sup>2</sup> ) - mean (SD)	72.72 (65.75)	68.70 (45.34)	0.071
<b>Cause of arrest - n (%):</b>			0.920
Hemorrhage	1 ( 1.5)	1 ( 2.9)	
Myocardial infarction/ischemia	7 (10.6)	8 ( 23.5)	
Other	18 (27.3)	12 ( 35.3)	
Primary arrhythmia	3 ( 4.5)	5 ( 14.7)	
Respiratory insufficiency	17 (25.8)	7 ( 20.6)	

Sepsis / infection	18 (27.3)	1 ( 2.9)	
Stroke / thromboembolism	2 ( 3.0)	0 ( 0.0)	
<b>Early interventions - n (%):</b>			
Witnessed arrest - n (%)	86 (76.8)	53 ( 79.1)	0.056
ECG monitoring - n (%)	56 (50.5)	33 ( 50.0)	0.009
CPR before AGA - n (%)	90 (92.8)	55 ( 94.8)	0.085
Defibrillated before AGA - n (%)	13 (13.8)	5 ( 8.9)	0.155
Ventilated before AGA- n (%)	49 (56.3)	25 ( 53.2)	0.063
Shockable rhythm - n (%)	22 (20.8)	7 ( 11.5)	0.254
Defibrillated, any - n (%)	29 (26.4)	11 ( 16.9)	0.231
Intubated - n (%)	61 (57.0)	38 ( 58.5)	0.029
Adrenaline given - n (%)	76 (70.4)	48 ( 76.2)	0.132
Antiarrhythmics - n (%)	11 (10.4)	6 ( 9.7)	0.023
Mechanical compressions - n (%)	12 (10.9)	5 ( 8.1)	0.097
Active temperature control - n (%)	2 (6.1)	3 ( 20.0)	0.423
<b>Status at rescue team arrival - n</b>			
Consciousness - n (%)	11 (11.3)	6 (10.7)	0.020
Breathing - n (%)	18 (18.6)	11 (19.6)	0.028
Pulse - n (%)	22 (22.7)	13 (23.2)	0.013
<b>Follow-Up data - n (%):</b>			
Angiography - n (%)	4 (12.1)	4 (26.7)	0.374
PCI - n (%)	2 (6.1)	2 (13.3)	0.248
Pacemaker implanted - n (%)	0 (0.0)	2 (13.3)	0.555
ICD implanted - n (%)	0 (0.0)	1 ( 6.7)	0.378
ROSC - n (%)	40 (35.4)	24 (35.3)	0.002
Death at 30 days - n (%)	85 (75.2)	56 (82.4)	0.175
Death overall - n (%)	85 (75.2)	56 (82.4)	0.175
Discharged alive - n (%)	16 (22.2)	6 (14.0)	0.216


**SD = standard deviation; IQR = interquartile range; SMD = standardized mean difference (difference between the means for the two groups divided by their mutual standard deviation. Values below 0.1 (10%) are considered inconsequential (i.e., no significant difference between the groups)). CPR = cardiopulmonary resuscitation, PCI = percutaneous coronary intervention, ICD = implantable cardioverter-defibrillator. ROSC = return of spontaneous circulation. AGA= alarm group arrival.**

Supplementary Figure 1: Missing data before and after imputation with MICE




**Supplementary Figure 1: Missing data before and after imputation with MICE.** A graphical view of the entire dataset is printed. Each column (variable) is depicted at the top and column color depicts type of variable. Each patient represents a row and white gaps indicate a missing data entry.

Supplementary Figure 2: Flow chart



**Supplementary Figure 2: Flow chart of the study population.** Patients who were less than 18 year of age, and cases occurring in the pre-pandemic period were excluded.


Supplementary Figure 3: Information on COVID-19 status during the study period.



**Supplementary Figure 3: Information on COVID-19 status during the study period.** No equals missing data, i.e. no information on COVID-19 status available. Yes equals, COVID +, COVID – or Unknown. In March only cases after 15/03/2020 were included.




Supplementary Figure 4: Distribution of age




Supplementary Figure 4: Distribution of age in relation to COVID-19 status.

Supplementary Figure 5: Etiology of IHCA, according to sex




Supplementary Figure 5A: Etiology of IHCA, men only.




Supplementary Figure 5B: Etiology of IHCA, women only.

Supplementary Figure 6: Conditions preceding IHCA, according to sex




Supplementary Figure 6A: Conditions preceding IHCA, men only.



Supplementary Figure 6B: Conditions preceding IHCA, women only.

Supplementary Figure 7: Cox adjusted survival curve for the overall population



**Supplementary Figure 7: Cox adjusted survival curve for the overall population, stratified on COVID-19 status.**

## STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page No
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2-3
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	2
Objectives	3	State specific objectives, including any prespecified hypotheses	2
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	2
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	2
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	2
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	2
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5-6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5
Bias	9	Describe any efforts to address potential sources of bias	3-4
Study size	10	Explain how the study size was arrived at	5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5-6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6-7
		(b) Describe any methods used to examine subgroups and interactions	6-7
		(c) Explain how missing data were addressed	6-7
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	6-7
		(e) Describe any sensitivity analyses	6-7

Continued on next page

<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7
		(b) Give reasons for non-participation at each stage	7
		(c) Consider use of a flow diagram	Supplementary material
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	7-8
		(b) Indicate number of participants with missing data for each variable of interest	7-8
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	7
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	8-9
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	7-10
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Supplementary material
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	11
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	13-14
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11-14
Generalisability	21	Discuss the generalisability (external validity) of the study results	14
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	14

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely

1  
2 available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at  
3 <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is  
4 available at [www.strobe-statement.org](http://www.strobe-statement.org).  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

# BMJ Open

## A Cohort Study of the Characteristics and Outcomes in Patients with COVID-19 and In-Hospital Cardiac Arrest

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-054943.R3
Article Type:	Original research
Date Submitted by the Author:	13-Nov-2021
Complete List of Authors:	<p>Holm, Astrid; University of Gothenburg, Department of Molecular and Clinical Medicine            Jerkeman, Matilda; University of Gothenburg, Department of Molecular and Clinical Medicine            Sultanian, Pedram; University of Gothenburg, Department of Molecular and Clinical Medicine            Lundgren, Peter; University of Gothenburg, Department of Molecular and Clinical Medicine; Kalmar County Hospital, Department of Internal Medicine            Ravn-Fischer, Annica; University of Gothenburg, Department of Molecular and Clinical Medicine            Israelsson, Johan; Kalmar County Hospital, Department of Internal Medicine; Linnaeus University, Faculty of Health and Life Sciences            Giesecke, Jasna; Danderyd University Hospital            Herlitz, Johan; University of Borås, Centre for Prehospital Research            Rawshani, Araz; University of Gothenburg, Department of Molecular and Clinical Medicine</p>
<b>Primary Subject Heading</b>:	Cardiovascular medicine
Secondary Subject Heading:	Cardiovascular medicine, Infectious diseases
Keywords:	COVID-19, CARDIOLOGY, Adult cardiology < CARDIOLOGY, Coronary heart disease < CARDIOLOGY

SCHOLARONE™  
Manuscripts





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

# A Cohort Study of the Characteristics and Outcomes in Patients with COVID-19 and In-Hospital Cardiac Arrest

Astrid Holm, MD<sup>1</sup>, Matilda Jerkeman, MD<sup>1</sup>, Pedram Sultanian, MD<sup>1</sup>, Peter Lundgren, MD, PhD<sup>1,3,7</sup>, Annica Ravn-Fischer, MD, PhD, Docent<sup>1</sup>, Johan Israelsson, PhD<sup>3,4</sup>, Jasna Giesecke, RN<sup>5</sup>, Johan Herlitz, MD, PhD<sup>2,6</sup>, Araz Rawshani, MD, PhD<sup>1,2</sup>

## Affiliations:

<sup>1</sup>Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden

<sup>2</sup>The Swedish Registry for Cardiopulmonary Resuscitation, Centre of Registries, Västra Götaland County, Sweden

<sup>3</sup>Department of Internal Medicine, Division of Cardiology, Kalmar County Hospital, Region Kalmar County, Sweden

<sup>4</sup>Faculty of Health and Life Sciences, Linnaeus University, Kalmar, Sweden

<sup>5</sup>RN, Lead CPR coordinator, Clinicum- Centre for clinical skills, interprofessional education and advanced medical simulation, Danderyd University Hospital, Stockholm, Sweden

<sup>6</sup>Prehospiten – Centre for Prehospital Research, University of Borås, Borås, Sweden

<sup>7</sup>Region Västra Götaland, Sahlgrenska University Hospital, Department of Cardiology, Gothenburg, Sweden

## Contact information:

Astrid Holm

Email: [astrid.holm@gu.se](mailto:astrid.holm@gu.se)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Phone: +358 400707722

**Manuscript word count:** 3088

## Abstract

**Objective:** We studied characteristics, survival, causes of cardiac arrest, conditions preceding cardiac arrest, predictors of survival, and trends in the prevalence of COVID-19 among in-hospital cardiac arrest (IHCA) cases.

**Design and setting:** Registry-based observational study.

**Participants:** We studied all cases ( $\geq 18$  years of age) of IHCA receiving cardiopulmonary resuscitation (CPR) in the Swedish Registry for Cardiopulmonary Resuscitation during 15/03/2020 to 31/12/2020. A total of 1613 patients were included and divided into the following groups: ongoing infection (**COVID+**; n=182), no infection (**COVID-**; n=1062) and unknown/not assessed (**UNA**; n=369).

**Main outcomes and measures:** We studied monthly trends in proportions of COVID-19 associated IHCAs, causes of IHCA in relation to COVID-19 status, clinical conditions preceding the cardiac arrest and predictors of survival.

**Results:** The rate of COVID+ patients suffering an IHCA increased to 23% during the first pandemic wave (April), then abated to 3% in July, and then increased to 19% during the second wave (December). Among COVID+ cases, 43% had respiratory insufficiency or

1  
2  
3 infection as the underlying cause of the cardiac arrest, compared to 18% among COVID–  
4  
5  
6 cases. The most common clinical sign preceding cardiac arrest was hypoxia (57%) among  
7  
8  
9 COVID+ cases. Odds ratio for 30-day survival for COVID+ cases was 0.50 (95% CI 0.33–  
10  
11  
12 0.76), compared with COVID– cases.  
13  
14  
15

16  
17 **Conclusion:** During pandemic peaks, up to one fourth of all IHCA are complicated by  
18  
19 COVID-19, and these patients have halved chance of survival, with women displaying the  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

## Article Summary

### Strengths and limitations of this study

- A major strength of our study is that it includes all IHCA in Sweden which were reported to the Swedish Registry for Cardiopulmonary Resuscitation.
- The sample recorded in the Swedish Registry for Cardiopulmonary Resuscitation is unbiased since all hospitals participate in the registry and all hospitals report data on COVID-19 status

- A limitation is that we do not know the severity of the COVID-19 infection, and we do not know if COVID-19 was the main reason for admission to hospital.
- Our study only includes IHCA's receiving CPR which leaves out all other patients with IHCA, e.g with a Do Not Attempt Resuscitation order.

## Introduction

The COVID-19 pandemic has, as of Nov 6<sup>th</sup> 2021, infected over 249 million individuals and lead to the death of over 5 million individuals (1). COVID-19 is now the third leading cause of death in Sweden (2, 3). Multiple studies have demonstrated that in-hospital cardiac arrest (IHCA) among patients with COVID-19 is associated with poor survival (4-7). A recent study demonstrated that hypoxia was the main cause of cardiac arrest among 40% of patients with COVID-19 and IHCA (6).

We have previously reported on COVID-19 and IHCA in the Swedish Registry for Cardiopulmonary Resuscitation (SRCR), showing a 2.3-fold increase in 30-day mortality among cases with COVID-19, compared to pre-pandemic cases. This was mainly driven by a 9-fold increase in mortality among women with COVID-19. At the time, no case of IHCA with COVID-19 had been discharged alive (8). The current study expands our previous investigation, including more patients, longer follow-up and emphasizes on the causes of

1  
2  
3 cardiac arrest, predictors of survival, coexisting conditions, and trends in the prevalence of  
4  
5  
6 COVID-19 among IHCA cases.  
7  
8  
9

## 10 11 12 **Methods**

### 13 14 15 **Data sources**

16  
17 This study is a registry-based observational study with data obtained from the SRCR during  
18  
19 the time period 15/03/2020 to 31/12/2020. The SRCR is a national quality registry and has  
20  
21 included IHCA cases since 2005. The data is collected by trained nurses who report patient  
22  
23 data using a web-based protocol. The registry has previously been described in detail (9).  
24  
25  
26  
27  
28  
29

30  
31 Vital status was obtained from the Swedish Population Registry and the last day of follow up  
32  
33 was 31/12/2020.  
34  
35  
36  
37

### 38 39 **Study population**

40  
41 The study population included all patients  $\geq 18$  years of age suffering IHCA and receiving  
42  
43 CPR throughout Sweden during the period 15/03/2020 to 31/12/2020. We used 15th of March  
44  
45 as the start date of the pandemic as the Swedish Public Health Authority declared on March  
46  
47  
48  
49  
50  
51 16<sup>th</sup> 2020 that community spread had commenced (3). On 1<sup>st</sup> of April the SRCR started  
52  
53 collecting data regarding COVID-19 status, and retrospectively identified 60 patients with  
54  
55  
56  
57 COVID-19 who suffered IHCA during March (they were included in the study). Patients were  
58  
59  
60

1  
2  
3 divided into the following three groups: ongoing infection (COVID+; n=182), no infection  
4  
5  
6 (COVID-; n=1062) and unknown/not assessed (UNA; n=369). COVID+ was defined as  
7  
8  
9 patients registered with an ongoing COVID-19 infection, suspected ongoing infection or  
10  
11 patients with a recent infection (n=29). The UNA group was included in the study in order to  
12  
13  
14 provide a complete picture of cases enrolled in the SRCR during the time period, and to  
15  
16  
17 evaluate whether missingness in COVID-19 status could entail selection bias.  
18  
19  
20  
21  
22  
23

### 24 **Variable definitions**

25  
26 In SRCR a patient with cardiac arrest was defined as an unconscious patient with no or  
27  
28 abnormal breathing, in whom resuscitation or defibrillation was attempted. IHCA was defined  
29  
30 as cardiac arrest in patients admitted to the hospital.  
31  
32  
33

34  
35 With regards to previous coexisting conditions, heart failure was defined as any heart failure  
36  
37 described before cardiac arrest. Kidney failure was defined as estimated glomerular filtration  
38  
39 rate (eGFR) below 60 ml/min/1.73 m<sup>2</sup>, calculated using the highest creatinine before cardiac  
40  
41  
42 arrest with Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. The  
43  
44  
45 SRCR records data on the highest creatinine levels analyzed up to six months prior to CA.  
46  
47  
48  
49  
50  
51

52  
53 Diabetes was defined as any diabetes diagnosis, regardless of type. Cancer was defined as any  
54  
55  
56 previously known cancer. Acute myocardial infarction (MI) was defined as an MI within 72  
57  
58  
59  
60



1  
2  
3 hours of CA. Previous myocardial infarction was defined as MI occurring earlier than 72  
4  
5  
6  
7 hours preceding the CA.  
8  
9

10 Regarding clinical conditions one hour prior to CA, arrhythmia was defined as any  
11  
12  
13 arrhythmia, hypoxia was defined as an oxygen saturation below 90%, hypotension was  
14  
15  
16 defined as systolic blood pressure below 90 mmHg, seizure was defined as any seizure with  
17  
18  
19 loss of consciousness, and heart failure was defined as any heart failure with pulmonary  
20  
21  
22 edema or severe shortness of breath with rales.  
23  
24

25  
26  
27 Wards with monitoring included the coronary care unit (CCU), intensive care unit (ICU),  
28  
29  
30 operating room (OR), emergency room (ER), high dependency unit (HDU) or the  
31  
32  
33 catheterization laboratory.  
34  
35

### 36 37 38 **Statistical analyses** 39

40 Patient characteristics are reported in means and medians, along with standard deviations and  
41  
42  
43 interquartile ranges, respectively. The Kaplan-Meier estimator was used for describing  
44  
45  
46 survival distributions; the log rank test was used to test for differences in survival. Trends in  
47  
48  
49 rates of COVID-19 were assessed on a monthly basis during the entire study basis.  
50  
51

52  
53  
54 Logistic regression was used to calculate odds ratios for 30-days survival. These models  
55  
56  
57 assessed the association between COVID-19 status and 30-days survival, adjusting for age,  
58  
59  
60

1  
2  
3 sex and initial rhythm (shockable or non-shockable). We performed subgroup analyses in  
4  
5  
6  
7 relation to sex, age and coexisting conditions (heart failure, cancer, diabetes, kidney failure  
8  
9  
10 and myocardial infarction). These subgroup analyses served to clarify whether the association  
11  
12  
13 between COVID status and survival was modified by age, sex or coexisting conditions.  
14

15  
16  
17 In order to obtain estimates of overall survival, we used Cox proportional hazards model with  
18  
19  
20 hours since CA as the time scale. The proportional hazards assumption was fulfilled for all  
21  
22  
23  
24 variables.  
25

26  
27  
28 We used the MICE (Multiple Imputation By Chained Equations) algorithm to impute missing  
29  
30  
31 values (10, 11) (Supplementary Figure 1). The imputed data set was used to calculate odds  
32  
33  
34 ratios for 30-days survival in the overall group, as well as in COVID+ and COVID- cases.  
35

36  
37  
38 These models included age, sex, initial rhythm, time to start of cardiopulmonary resuscitation  
39  
40  
41 (CPR), time of CA, previous MI, type of ward, heart failure, ECG monitoring, diabetes and  
42  
43  
44 acute MI.  
45

46  
47  
48 Analyses were done in R (v. 4.0.3, R Foundation for Statistical Computing) using RStudio.  
49

#### 50 51 52 **Patient and Public Involvement statement:**

53  
54  
55 No patients were involved.  
56  
57  
58  
59  
60

## Results

A total of 2,227 patients were enrolled in the SRCR between 01/01/2020 and 31/12/2020.

After excluding patients <18 years (n=68) and pre-pandemic cases (n=546), 1,613 cases

remained from 15/03/2020 to 31/12/2020 and constituted the final study population

(Supplementary Figure 2). There was a high rate of information on COVID-19 status during

the study period among patients registered in the registry (Supplementary Figure 3).

### Baseline characteristics

The overall mean age was 70.8 years, and the proportion of women was 37.6%. At the end of

follow-up, 341 (32.7%) patients were alive. The mean age was similar in the three groups:

70.9 years in COVID+, 71.0 years in COVID– cases, and 70.2 years in cases with UNA

(Supplementary Figure 4). The proportion of women was also similar; 37.6% in COVID+ and

36.6% in COVID– and 41.0% in UNA cases.

A regular ward was the most common place for cardiac arrest in all 3 groups; 45.1% of

COVID+, 44.1% of COVID– and 31.4% of UNA cases occurred in regular wards (Table 1).

The emergency room (ER) was the second most common location for COVID+ cases

(15.9%).

1  
2  
3 Regarding comorbidities, acute myocardial infarction was observed in 12.0% of COVID+ and  
4  
5  
6 23.6% of COVID- cases. Previous myocardial infarction was observed in 11.7% of COVID+,  
7  
8  
9  
10 20.8% of COVID- and 11.7% of UNA cases. The prevalence of heart failure, cancer and  
11  
12  
13 diabetes was similar across all groups (Table 1).  
14

15  
16  
17 Fewer cases among COVID+ individuals had a shockable rhythm (17.3%), compared with  
18  
19  
20 COVID- (24.9%) cases. Likewise, fewer cases among COVID+ (22.7%) were defibrillated,  
21  
22  
23 compared with COVID- cases (31.5%). COVID+ cases were ventilated in 54.8% of cases  
24  
25  
26 before rescue team arrival, as compared with 63.2% in COVID- cases.  
27  
28  
29

### 30 31 **Follow-up**

32  
33 Return of spontaneous circulation (ROSC) after initial resuscitation, was less common in  
34  
35  
36 COVID+ cases, as compared with COVID- cases. Also, angiography, PCI, pacemaker and  
37  
38  
39 ICD implantation post cardiac arrest were less common in COVID+ cases.  
40  
41  
42  
43  
44  
45  
46  
47  
48

### 49 **Sex specific characteristics**

50  
51 Acute myocardial infarction was observed in 21.2% of COVID+ women and 7.6% of  
52  
53  
54 COVID+ men. Previous myocardial infarction was observed in 4.7% of COVID+ women and  
55  
56  
57 16.2% of COVID+ men. The prevalence of previous stroke, renal failure, heart failure, cancer  
58  
59  
60

1  
2  
3 and diabetes were similar among men and women, as was location at the time of cardiac  
4  
5  
6  
7 arrest. COVID+ men were more likely to have a shockable rhythm (20.8%) compared with  
8  
9  
10 COVID+ women (11.5%), and to be defibrillated (26.4% in men vs. 16.9% in women)  
11  
12  
13 (Supplementary Table 1).  
14  
15  
16  
17

### 18 **Monthly trends in COVID-19 associated IHCA**

19

20 In March, April and May 14%, 23% and 20% of patients suffering IHCA were COVID+ (data  
21  
22  
23 from 16<sup>th</sup> March). The proportion of COVID+ cases diminished rapidly during June to July.  
24  
25  
26  
27 From September onwards the COVID+ cases increased again to reach 19% in December. In  
28  
29  
30 Figure 1A additional details regarding monthly variations are presented.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Etiology of IHCA

The most common cause of IHCA among COVID+ cases was respiratory insufficiency (24%, n=24), and the second most common cause was sepsis or other infection (19%, n=19).

Respiratory insufficiency and sepsis/other infection were less common in the other groups (Figure 1B), which instead displayed higher rates of acute myocardial infarction.

## Clinical conditions one hour prior to IHCA

As evident in Figure 1C, which describes the clinical conditions preceding (up to 60 minutes) the cardiac arrest, hypoxia was more common among COVID+ cases (57%), as compared with COVID- cases (34%).

## Survival analysis

The Kaplan Meier plots (Figure 2) show that COVID+ cases generally had a lower probability of survival compared to both COVID- and UNA cases. The overall 30-day survival (Figure 2A) was 21% among COVID+, compared with 36% in COVID- cases (p=0.00086). The subgroup analysis of women (Figure 2B) showed low survival rates in COVID+ cases (16% 30-day survival). The subgroup analysis of men (Figure 2C) showed low survival rates in COVID+ cases (23% 30-day survival). The 30 days survival among COVID+ aged >70 years was 18% (Figure 2D), as compared with 25% of COVID+ cases aged 70 years or younger (Figure 2E). Survival curves for the subgroups of individuals with

1  
2  
3 cancer, heart failure and diabetes, did not display any distinct patterns (Figure 2F-2H), with  
4  
5  
6 all p values >0.1. Patients with kidney failure had a 30 days survival of 13% among COVID+  
7  
8  
9 cases (Figure 2I). Patients with acute MI had a 30 days survival of 8% among COVID+ cases  
10  
11  
12  
13 (Figure 2J).

14  
15  
16  
17 Cox adjusted survival curves are presented in Supplementary Figure 5; COVID+ cases  
18  
19  
20 displayed the lowest probability of survival, whereas there was no material difference  
21  
22  
23  
24 between COVID- and UNA cases.

### 25 26 27 **Odds ratios for 30-days survival**

28  
29  
30 When adjusted for age, sex and initial rhythm the odds ratios for 30-day survival, comparing  
31  
32  
33 COVID+ vs. COVID-, were 0.50 (0.33-0.76) overall, 0.53 (0.31-0.88) for men, and 0.44  
34  
35  
36 (0.20-0.88) for women. In the subgroup of patients with heart failure, myocardial infarction  
37  
38  
39 and cancer, we found no statistically significant associations, whereas in the subgroup of  
40  
41  
42  
43 COVID+ patients with kidney failure, odds ratio for 30-days survival was 0.43 (0.16-0.99),  
44  
45  
46 when compared with COVID- cases (Figure 3).

### 47 48 49 **Predictors of survival**

50  
51  
52  
53 Regarding predictors of 30-days survival among COVID+ we note that confidence intervals  
54  
55  
56 were generally wide. Lack of ECG monitoring and delayed start of CPR showed point  
57  
58  
59  
60

1  
2  
3 estimates below 1.0, although non-significant. Odds ratio for patients treated in non-  
4  
5  
6 monitored wards was 0.26 (95% CI 0.08-0.78) as compared with monitored wards (Figure 4).  
7  
8  
9

10 No coexisting condition was associated with survival among COVID+ cases.  
11  
12

13  
14 Among COVID- cases, the factors that were significantly associated with 30-days survival  
15  
16 were shockable rhythm (OR 4.18 [95% CI 2.69–6.02]), ECG monitoring (2.67 [95% CI 1.82–  
17  
18 3.95]), heart failure (OR 0.58 [95% CI 0.40–0.83]) and diabetes (OR 0.64 [95% CI 0.44–  
19  
20 0.92]; Figure 4).  
21  
22  
23  
24  
25  
26  
27  
28

## 29 Discussion

30  
31  
32 This study elucidates characteristics and outcomes in patients with COVID-19 who develop  
33  
34 IHCA. We show that the prevalence of COVID-19 among patients suffering an IHCA  
35  
36 increased to approximately one in four cardiac arrests during the first pandemic wave, and  
37  
38 one in five cardiac arrests during the second wave. In IHCA the probability of survival to 30-  
39  
40 days is halved by the presence of COVID-19.  
41  
42  
43  
44  
45  
46  
47  
48

49 Regarding location of CA, we note that the most common location for COVID+ patients was  
50  
51 regular wards, which are not monitored. This is unfortunate since our analyses showed that  
52  
53 type of ward (monitored vs non-monitored) was significantly associated with survival, such  
54  
55 that COVID+ cases in non-monitored wards displayed 74% lower probability of survival as  
56  
57  
58  
59  
60



1  
2  
3 compared with COVID+ cases in monitored wards. As compared with COVID– cases,  
4  
5  
6  
7 cardiac arrest in the ER was more common in COVID+ cases. The often rapid deterioration of  
8  
9  
10 cardiopulmonary function in patients with COVID-19 may be one of the explanations for this  
11  
12  
13 finding. Fewer COVID+ cases were located in the CCU, which was an expected finding given  
14  
15  
16 that cardiac etiology was less common among these patients.  
17  
18  
19

20  
21 We note that the most common cause of cardiac arrest in COVID+ cases, as well as the most  
22  
23  
24 frequent clinical condition directly preceding the arrest, was respiratory. A total of 57% of  
25  
26  
27 cases displayed hypoxia before cardiac arrest. This may highlight an opportunity for  
28  
29  
30 improving outcomes; measures to prevent hypoxia and to correct it immediately may reduce  
31  
32  
33 the risk of cardiac arrest in patients with COVID-19. The high rate of respiratory etiology was  
34  
35  
36 driven by men (Supplementary Figure 6-7).  
37  
38  
39

40  
41 However, the fact that 43% of cases with COVID-19 did not have hypoxia prior to cardiac  
42  
43  
44 arrest suggests that other factors are important as well. Thromboembolism, myocardial  
45  
46  
47 infarction, arrhythmias, etc. may all contribute to the development of a cardiac arrest (12).  
48  
49  
50

51  
52 A previous study from Wuhan showed that 87.5% of COVID+ cases with IHCA had a  
53  
54  
55 respiratory etiology and a study from Southwest Georgia that 53% of the patients with IHCA  
56  
57  
58 and COVID-19 had ARDS (5, 7).  
59  
60

1  
2  
3 The survival rates were poor among COVID+ patients with an overall 30-days survival of  
4  
5  
6  
7 21%, compared to 36% among COVID-. The survival rate was, however, not as low as in the  
8  
9  
10 study from Wuhan, in which 3% (151 patients studied) survived, or in the study from New  
11  
12  
13 York with 31 patients or in the study from Southwest Georgia with 63 patients with none  
14  
15  
16 surviving (5, 7, 13). One reason for the poor survival could be the small number of patients  
17  
18  
19 found in shockable rhythm (17% vs. 25% for COVID+ and COVID-, respectively) since  
20  
21  
22 patients with shockable rhythm have a more favorable outcome. After adjusting for sex, age  
23  
24  
25 and shockable rhythm the 30-day survival was still significantly worse among patients with  
26  
27  
28 an ongoing infection.  
29  
30  
31

32  
33  
34 We demonstrate that COVID+ women had halved chance of survival at 30 days, compared  
35  
36  
37 with COVID- women. We find it interesting that COVID+ women had acute MI three times  
38  
39  
40 as often as men, despite the fact that men exhibited shockable rhythm – and were defibrillated  
41  
42  
43 – twice as often as women.  
44  
45  
46  
47

48 **Strengths and limitations.** This study includes all IHCA in Sweden which were reported to  
49  
50  
51 SRCR. The sample recorded in the SRCR is unbiased since all hospitals participate in the  
52  
53  
54 registry and all hospitals report data on COVID-19 status. However, we do not know the  
55  
56  
57 severity of the COVID-19 infection, and we do not know if COVID-19 was the main reason  
58  
59  
60

1  
2  
3 for admission to hospital. With regards to the classification of COVID-19 status, we have  
4  
5  
6 performed a misclassification analysis which demonstrated that odds ratios were not  
7  
8  
9  
10 materially affected by misclassification bias. Missingness was prevalent with regards to cause  
11  
12  
13 of cardiac arrest, which is due to the difficulties determining this factor. However, we find no  
14  
15  
16 reason to believe that missingness differs across COVID status categories, and it should  
17  
18  
19 therefore not bias our inferences. Our study only includes IHCAs receiving CPR. This leaves  
20  
21  
22 out all other patients with IHCA, e.g with a Do Not Attempt Resuscitation order.  
23  
24  
25  
26  
27 Our regression models that included only COVID-19 cases should be interpreted with caution  
28  
29  
30 due to the large number of predictors in the model, with relatively few patients (resulting in  
31  
32  
33 wide confidence intervals). Further studies are warranted, using a larger study population, and  
34  
35  
36 a longer follow up especially regarding subgroup analyses, neurological outcomes and the  
37  
38  
39 quality of life for these patients.  
40  
41  
42  
43  
44

## 45 **Conclusion**

46  
47  
48 During pandemic peaks, up to one fourth of all IHCAs are complicated by COVID-19, and  
49  
50  
51 these patients have halved chance of survival, with women displaying the worst outcomes.  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Funding

This work was supported by the Swedish Research Council [2019-02019] and the Swedish Heart and Lung Foundation [20200261].

**Conflict of interest:** none declared.

**Author Statement:** Astrid Holm and Araz Rawshani designed the study. Astrid Holm wrote the first draft of the manuscript, analyzed all data and made initial interpretations of data.

Araz Rawshani has been supervising. Matilda Jerkeman, Pedram Sultanian, Peter Lundgren, Annica Ravn-Fischer, Johan Israelsson, Jasna Giesecke and Johan Herlitz revised the article critically for important intellectual content and approved the version of the article to be published.

**Ethics statement:** The study was approved by the Swedish Ethical Review Authority (ID 2020-02017). The data was anonymized before the authors accessed it for the purpose of the study.

**Data sharing plan:** No additional data available

## References

1. Johns Hopkins University and Medicine COVID-19 map [internet] Johns Hopkins Coronavirus Resource Centre 2020. [updated 13/5/2021. Available from: <https://coronavirus.jhu.edu/map.html>.
2. Dödsorsaker första halvåret 2020. Socialstyrelsen. Hälsa- och sjukvård.; 2020 17/11/2020.
3. Andersson J. Samhällsspridning av coronaviruset i Sverige. Läkartidningen. 16/03/2020.
4. Hayek SS, Brenner SK, Azam TU, Shadid HR, Anderson E, Berlin H, et al. In-hospital cardiac arrest in critically ill patients with covid-19: multicenter cohort study. *Bmj*. 2020;371:m3513.
5. Shah P, Smith H, Olarewaju A, Jani Y, Cobb A, Owens J, et al. Is Cardiopulmonary Resuscitation Futile in Coronavirus Disease 2019 Patients Experiencing In-Hospital Cardiac Arrest? *Crit Care Med*. 2021;49(2):201-8.
6. Mitchell OJL, Yuriditsky E, Johnson NJ, Doran O, Buckler DG, Neefe S, et al. In-hospital cardiac arrest in patients with coronavirus 2019. *Resuscitation*. 2021;160:72-8.
7. Shao F, Xu S, Ma X, Xu Z, Lyu J, Ng M, et al. In-hospital cardiac arrest outcomes among patients with COVID-19 pneumonia in Wuhan, China. *Resuscitation*. 2020;151:18-23.
8. Sultanian P, Lundgren P, Strömsöe A, Aune S, Bergström G, Hagberg E, et al. Cardiac arrest in COVID-19: characteristics and outcomes of in- and out-of-hospital cardiac arrest. A report from the Swedish Registry for Cardiopulmonary Resuscitation. *European Heart Journal*. 2021.
9. Hessulf F, Herlitz J, Rawshani A, Aune S, Israelsson J, Södersved-Källestedt ML, et al. Adherence to guidelines is associated with improved survival following in-hospital cardiac arrest. *Resuscitation*. 2020;155:13-21.
10. Stef van Buuren, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations in R. *Journal of Statistical Software*. 2011;Vol 45.
11. 3.5 Classification and regression trees [Available from: <https://stefvanbuuren.name/fimd/sec-cart.html>.
12. Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary manifestations of COVID-19. *Nat Med*. 2020;26(7):1017-32.
13. Sheth V, Chishti I, Rothman A, Redlener M, Liang J, Pan D, et al. Outcomes of in-hospital cardiac arrest in patients with COVID-19 in New York City. *Resuscitation*. 2020;155:3-5.

**Table 1** Characteristics of 1613 patients with IHCA during the COVID-19 pandemic.

Variables	No infection COVID –	Ongoing infection COVID +	Unknown/NA UNA	SMD
<b>n</b>	1062	182	369	
<b>Demographics:</b>				
Age - mean (SD)	71.00 (13.32)	70.93 (12.43)	70.22 (13.60)	0.039
Woman - n (%)	388 (36.6)	68 (37.6)	151 (41.0)	0.061
<b>Location of cardiac arrest - n (%)</b>				0.527
Coronary care unit - n (%)	155 (14.6)	14 ( 7.7)	50 (13.6)	
Intensive care unit - n (%)	77 ( 7.3)	25 (13.7)	19 ( 5.1)	
Operational room - n (%)	22 ( 2.1)	0 ( 0.0)	12 ( 3.3)	
Emergency room - n (%)	139 (13.1)	29 (15.9)	65 (17.6)	
Outpatient lab, radiology - n (%)	49 ( 4.6)	7 ( 3.8)	28 ( 7.6)	
Cathlab - n (%)	98 ( 9.2)	8 ( 4.4)	60 (16.3)	
Intermediate care unit - n (%)	25 ( 2.4)	15 ( 8.2)	10 ( 2.7)	
Regular ward - n (%)	468 (44.1)	82 (45.1)	116 (31.4)	
Other - n (%)	29 ( 2.7)	2 ( 1.1)	9 ( 2.4)	
<b>Critical times - median (IQR):</b>				
Time to alert – median (IQR)	1.00 [1.00, 1.00]	1.00 [1.00, 1.00]	1.00 [1.00, 1.00]	0.078
Time to CPR - median (IQR)	0.00 [0.00, 1.00]	0.00 [0.00, 0.00]	0.00 [0.00, 1.00]	0.109
Time to defibrillation - median (IQR)	2.00 [1.00, 5.00]	2.00 [1.00, 4.75]	1.00 [1.00, 4.00]	0.141
<b>Comorbidities - n (%):</b>				
MI, ongoing - n (%)	178 (23.6)	12 (12.0)	37 (29.4)	0.292
MI, previous - n (%)	163 (20.8)	13 (11.7)	26 (18.4)	0.165
Stroke, ongoing - n (%)	30 ( 3.8)	4 ( 3.7)	4 ( 3.0)	0.030
Stroke, previous - n (%)	82 (10.3)	7 ( 6.1)	15 (10.5)	0.105
Cancer, any - n (%)	165 (20.9)	20 (17.7)	28 (20.6)	0.054
Diabetes - n (%)	224 (27.9)	36 (31.0)	38 (27.0)	0.060
Heart failure - n (%)	229 (29.7)	36 (33.0)	36 (27.9)	0.074
Ejection fraction (%) - mean (SD)	46.14 (13.74)	46.44 (11.86)	44.94 (14.82)	0.073
EF <50% - n (%)	167 (46.0)	26 (48.1)	22 (46.8)	0.029
<b>Kidney function category - n (%)</b>				0.121
eGFR <30 - n (%)	165 (21.6)	22 (20.0)	26 (20.0)	
eGFR 30–59 - n (%)	216 (28.3)	32 (29.1)	44 (33.8)	
eGFR 60–89 - n (%)	198 (25.9)	25 (22.7)	30 (23.1)	
eGFR ≥90 - n (%)	185 (24.2)	31 (28.2)	30 (23.1)	
No kidney failure (eGFR ≥60) - n (%)	383 (50.1)	56 (50.9)	60 (46.2)	0.063
eGFR (ml/min/m <sup>2</sup> ) - mean (SD)	66.89 (49.43)	71.26 (58.96)	63.78 (40.31)	0.099
<b>Cause of arrest: - n (%)</b>				0.629
Hemorrhage - n (%)	34 (4.9)	2 (2.0)	10 (8.1)	
Myocardial infarction/ischemia - n (%)	181 (26.2)	15 (14.9)	41 (33.3)	

infarction/ischemi a	181 (26.2 )	15 (14.9 )	4 (33.3 )				
Other - n (%)	213 (30.8)	30 (29.7)	41 (33.3)				
Primary arrhythmia - n (%)	101 (14.6)	8 (7.9)	12 (9.8)				
Respiratory insufficiency - n (%)	73 (10.5)	24 (23.8)	7 (5.7)				
Sepsis/infection - n (%)	45 (6.5)	19 (18.8)	4 (3.3)				
Stroke/thromboembolism - n (%)	45 (6.5)	3 (3.0)	8 (6.5)				
<b>Early interventions - n (%):</b>							
Witnessed arrest - n (%)	857 (80.9)	140 (77.8)	306 (85.0)	0.124			
ECG monitoring - n (%)	635 (60.5)	89 (50.0)	221 (62.1)	0.163			
CPR before AGA - n (%)	845 (91.0)	146 (93.6)	268 (88.2)	0.127			
Defibrillated before AGA - n (%)	159 (17.9)	18 (11.9)	53 (19.0)	0.131			
Ventilated before AGA - n (%)	503 (63.2)	74 (54.8)	175 (69.2)	0.199			
Shockable rhythm - n (%)	247 (24.9)	29 (17.3)	90 (27.0)	0.158			
Defibrillated, any - n (%)	323 (31.5)	40 (22.7)	111 (32.8)	0.151			
Intubated - n (%)	473 (47.0)	100 (57.8)	177 (53.8)	0.145			
Adrenaline given - n (%)	668 (65.6)	125 (72.7)	223 (66.4)	0.102			
Antiarrhythmics - n (%)	139 (14.1)	17 (10.1)	48 (15.4)	0.107			
Mechanical compressions - n (%)	109 (10.8)	18 (10.4)	66 (20.0)	0.180			
Active temperature control - n (%)	54 (11.3)	5 (10.4)	3 (4.4)	0.173			
<b>Status at rescue team arrival - n (%):</b>							
Consciousness - n (%)	214 (23.1)	18 (11.7)	57 (19.3)	0.204			
Breathing - n (%)	288 (31.2)	30 (19.5)	84 (28.7)	0.181			
Pulse - n (%)	309 (33.8)	36 (23.4)	89 (30.4)	0.154			
<b>Follow-Up data - n (%):</b>							
Angiography - n (%)	115 (24.2)	8 (16.7)	15 (20.8)	0.124			
PCI - n (%)	87 (18.2)	4 (8.3)	16 (21.9)	0.258			
Pacemaker implanted - n (%)	80 (16.7)	2 (4.2)	4 (5.6)	0.281			
ICD implanted - n (%)	36 (7.5)	1 (2.1)	2 (2.8)	0.172			
ROSC - n (%)	520 (49.0)	64 (35.2)	142 (38.5)	0.188			
Death at 30 days - n (%)	666 (62.7)	141 (77.5)	237 (64.2)	0.218			
Death overall - n (%)	703 (66.2)	141 (77.5)	241 (65.3)	0.181			

1  
2  
3  
4 SD = standard deviation; IQR = interquartile range; SMD = standardized mean difference (difference between  
5 the means for the two groups divided by their mutual standard deviation. Values below 0.1 (10%) are  
6 considered inconsequential (i.e., no significant difference between the groups)). CPR = Cardiopulmonary  
7 resuscitation, PCI = Percutaneous Coronary Intervention, ICD = implantable cardioverter-defibrillator. ROSC =  
8 return of spontaneous circulation. AGA= alarm group arrival  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

## 26 Figure Titles and Legends

27  
28 **Figure 1: Characteristics of IHCA according to COVID-19 status**

29  
30  
31  
32 **Figure 1A: Monthly proportion of COVID-19 status among patients with IHCA, stratified on**  
33  
34  
35 **COVID-19 status.** In March only cases after 15/03/2020 were included.

36  
37  
38  
39 **Figure 1B: Etiology of IHCA, stratified on COVID-19 status.** The y-axis shows percentages  
40  
41  
42 for each etiology in each group.

43  
44  
45  
46 **Figure 1C: Clinical conditions 1 hour prior to IHCA, stratified on COVID-19 status.** Only  
47  
48  
49 patients with data regarding the specific condition was included.

50  
51  
52  
53  
54  
55  
56 **Figure 2: Kaplan Meier survival curves**  
57  
58  
59  
60



1  
2  
3  
4 **Figure 2: Kaplan Meier survival curves**, separately for (A) Overall, (B) Women, (C) Men, (D)  
5  
6  
7 Age  $\geq 70$  year, (E) Age  $< 70$  year, (F) Cancer, (G) Heart failure, (H) Diabetes, (I) Kidney  
8  
9  
10 failure and (J) Myocardial infarction.  $p = \log$ -rank  $p$ -value. The numbers under the graphs are  
11  
12  
13 showing the survival in percentages. Regarding myocardial infarction acute MI is presented.  
14  
15  
16  
17  
18

19 **Figure 3: Odds Ratio for 30-day survival**

20  
21  
22  
23 **Figure 3: Forest plot with the adjusted odds ratio for 30-day survival among patients with**  
24  
25  
26 **ongoing infection vs. no infection and unknown/NA vs. no infection.** Stratified on overall,  
27  
28  
29 men, women, age  $< 70$  years, age  $\geq 70$  years, heart failure, kidney failure, diabetes,  
30  
31  
32  
33 myocardial infarction and cancer. Myocardial infarction was defined as acute or previous MI.  
34  
35  
36  
37  
38  
39

40 **Figure 4: Odds Ratio for 30-day survival**

41  
42  
43  
44 **Figure 4: Forest plot with odds ratio for 30-day survival**, stratified on the groups, no  
45  
46 infection, ongoing infection and overall, all in different colors. The 95% Confidence interval  
47  
48 is shown between the bars. X-axis has a logarithmic scale. ECG= electrocardiogram, CA=  
49  
50 cardiac arrest, MI= myocardial infarction. CI= confidence interval.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Figure 1: Characteristics of IHCA according to COVID-19 status





Figure 1A: Monthly proportion of COVID-19 status among patients with IHCA, stratified on COVID-19 status. In March only cases after 15/03/2020 were included.

Figure 1B: Etiology of IHCA, stratified on COVID-19 status. The y-axis shows percentages for each etiology in each group.

Figure 1C: Clinical conditions 1 hour prior to IHCA, stratified on COVID-19 status. Only patients with data regarding the specific condition was included.

Figure 2: Kaplan Meier survival curves



**Figure 2: Kaplan Meier survival curves, separately for (A) Overall, (B) Women, (C) Men, (D) Age ≥70 year, (E) Age <70 year, (F) Cancer, (G) Heart failure, (H) Diabetes, (I) Kidney failure and (J) Myocardial infarction. p= log-rank p-value. The numbers under the graphs are showing the survival in percentages. Regarding myocardial infarction acute MI is presented.**

Figure 3: Odds Ratio for 30-day survival





Figure 3: Forest plot with the adjusted odds ratio for 30-day survival among patients with ongoing infection vs. no infection and unknown/NA vs. no infection. Stratified on overall, men, women, age < 70 years, age ≥ 70 years, heart failure, kidney failure, diabetes, myocardial infarction and cancer. Myocardial infarction was defined as acute or previous MI.

Figure 4: Odds Ratio for 30-day survival



**Figure 4: Forest plot with odds ratio for 30-day survival, stratified on the groups, no infection, ongoing infection and overall, all in different colors. The 95% Confidence interval is shown between the bars. X-axis has a logarithmic scale. ECG= electrocardiogram, CA= cardiac arrest, MI= myocardial infarction. CI= confidence interval.**

1  
2  
3  
4 **Supplementary figures and tables**  
5  
6

7 **Characteristics and Outcomes in Patients**  
8 **with COVID-19 and In-Hospital Cardiac**  
9 **Arrest**  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Supplementary Table 1: Characteristics of COVID+ patients with IHCA in relation to sex.

**Supplementary Table 1:** Characteristics of 181 COVID+ patients with IHCA during the COVID-19 pandemic in relation to sex. One COVID+ patient had missing data on sex.


variables	Men	Women	SMD
<b>n</b>	113	68	
<b>Demographics:</b>			
Age - mean (SD)	71.39 (10.75)	70.35 (14.87)	0.080
<b>Location of cardiac arrest - n (%):</b>			0.249
Coronary care unit	7 ( 6.2)	7 ( 10.3)	
Intensive care unit	15 (13.3)	10 ( 14.7)	
Operational room	0 ( 0.0)	0 ( 0.0)	
Emergency room	17 (15.0)	11 ( 16.2)	
Outpatient lab, radiology	4 ( 3.5)	3 ( 4.4)	
Cathlab	6 ( 5.3)	2 ( 2.9)	
Intermediate care unit	11 ( 9.7)	4 ( 5.9)	
Regular ward	52 (46.0)	30 ( 44.1)	
Other	1 ( 0.9)	1 ( 1.5)	
<b>Critical times - median (IQR):</b>			
Time to alert – median (IQR)	1.00 [1.00, 1.00]	1.00 [1.00, 1.00]	0.256
Time to CPR - median (IQR)	0.00 [0.00, 0.00]	0.00 [0.00, 1.00]	0.031
Time to defibrillation - median	2.00 [1.00, 5.00]	2.00 [1.00, 2.00]	0.009
<b>Comorbidities - n (%):</b>			
MI, ongoing - n (%)	5 ( 7.6)	7 ( 21.2)	0.396
MI, previous - n (%)	11 (16.4)	2 ( 4.7)	0.391
Stroke, ongoing - n (%)	4 ( 5.8)	0 ( 0.0)	0.351
Stroke, previous - n (%)	5 ( 7.0)	2 ( 4.7)	0.102
Cancer, any - n (%)	13 (18.8)	6 ( 14.0)	0.132
Diabetes - n (%)	24 (33.3)	12 ( 27.9)	0.118
Heart failure - n (%)	23 (33.8)	13 ( 32.5)	0.028
Ejection fraction (%) - mean (SD)	44.84 (12.22)	49.31 (10.56)	0.392
EF <50% - n (%)	19 (51.4)	7 ( 43.8)	0.153
<b>Kidney function category - n (%):</b>			0.357
eGFR <30	16 (22.9)	6 ( 15.0)	
eGFR 30–59	17 (24.3)	15 ( 37.5)	
eGFR 60–89	18 (25.7)	7 ( 17.5)	
eGFR ≥90	19 (27.1)	12 ( 30.0)	
No kidney failure (eGFR ≥60)	37 (52.9)	19 ( 47.5)	0.107
eGFR (ml/min/m <sup>2</sup> ) - mean (SD)	72.72 (65.75)	68.70 (45.34)	0.071
<b>Cause of arrest - n (%):</b>			0.920
Hemorrhage	1 ( 1.5)	1 ( 2.9)	
Myocardial infarction/ischemia	7 (10.6)	8 ( 23.5)	
Other	18 (27.3)	12 ( 35.3)	
Primary arrhythmia	3 ( 4.5)	5 ( 14.7)	
Respiratory insufficiency	17 (25.8)	7 ( 20.6)	

Sepsis / infection	18 (27.3)	1 ( 2.9)	
Stroke / thromboembolism	2 ( 3.0)	0 ( 0.0)	
<b>Early interventions - n (%):</b>			
Witnessed arrest - n (%)	86 (76.8)	53 ( 79.1)	0.056
ECG monitoring - n (%)	56 (50.5)	33 ( 50.0)	0.009
CPR before AGA - n (%)	90 (92.8)	55 ( 94.8)	0.085
Defibrillated before AGA - n (%)	13 (13.8)	5 ( 8.9)	0.155
Ventilated before AGA- n (%)	49 (56.3)	25 ( 53.2)	0.063
Shockable rhythm - n (%)	22 (20.8)	7 ( 11.5)	0.254
Defibrillated, any - n (%)	29 (26.4)	11 ( 16.9)	0.231
Intubated - n (%)	61 (57.0)	38 ( 58.5)	0.029
Adrenaline given - n (%)	76 (70.4)	48 ( 76.2)	0.132
Antiarrhythmics - n (%)	11 (10.4)	6 ( 9.7)	0.023
Mechanical compressions - n (%)	12 (10.9)	5 ( 8.1)	0.097
Active temperature control - n (%)	2 (6.1)	3 ( 20.0)	0.423
<b>Status at rescue team arrival - n</b>			
Consciousness - n (%)	11 (11.3)	6 (10.7)	0.020
Breathing - n (%)	18 (18.6)	11 (19.6)	0.028
Pulse - n (%)	22 (22.7)	13 (23.2)	0.013
<b>Follow-Up data - n (%):</b>			
Angiography - n (%)	4 (12.1)	4 (26.7)	0.374
PCI - n (%)	2 (6.1)	2 (13.3)	0.248
Pacemaker implanted - n (%)	0 (0.0)	2 (13.3)	0.555
ICD implanted - n (%)	0 (0.0)	1 ( 6.7)	0.378
ROSC - n (%)	40 (35.4)	24 (35.3)	0.002
Death at 30 days - n (%)	85 (75.2)	56 (82.4)	0.175
Death overall - n (%)	85 (75.2)	56 (82.4)	0.175
Discharged alive - n (%)	16 (22.2)	6 (14.0)	0.216

**SD = standard deviation; IQR = interquartile range; SMD = standardized mean difference (difference between the means for the two groups divided by their mutual standard deviation. Values below 0.1 (10%) are considered inconsequential (i.e., no significant difference between the groups)). CPR = cardiopulmonary resuscitation, PCI = percutaneous coronary intervention, ICD = implantable cardioverter-defibrillator. ROSC = return of spontaneous circulation. AGA= alarm group arrival.**




## Supplementary Figure 1: Missing data before and after imputation with MICE




**Supplementary Figure 1: Missing data before and after imputation with MICE.** A graphical view of the entire dataset is printed. Each column (variable) is depicted at the top and column color depicts type of variable. Each patient represents a row and white gaps indicate a missing data entry.

Supplementary Figure 2: Flow chart




**Supplementary Figure 2: Flow chart of the study population.** Patients who were less than 18 year of age, and cases occurring in the pre-pandemic period were excluded.

Supplementary Figure 3: Information on COVID-19 status during the study period.




**Supplementary Figure 3: Information on COVID-19 status during the study period.** No equals missing data, i.e. no information on COVID-19 status available. Yes equals, COVID +, COVID – or Unknown. In March only cases after 15/03/2020 were included.

Supplementary Figure 4: Distribution of age




Supplementary Figure 4: Distribution of age in relation to COVID-19 status.

Supplementary Figure 5: Etiology of IHCA, according to sex




Supplementary Figure 5A: Etiology of IHCA, men only.




Supplementary Figure 5B: Etiology of IHCA, women only.

Supplementary Figure 6: Conditions preceding IHCA, according to sex




Supplementary Figure 6A: Conditions preceding IHCA, men only.



Supplementary Figure 6B: Conditions preceding IHCA, women only.

Supplementary Figure 7: Cox adjusted survival curve for the overall population



Supplementary Figure 7: Cox adjusted survival curve for the overall population, stratified on COVID-19 status.

## STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page No
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2-3
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	2
Objectives	3	State specific objectives, including any prespecified hypotheses	2
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	2
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	2
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	2
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	2
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5-6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5
Bias	9	Describe any efforts to address potential sources of bias	3-4
Study size	10	Explain how the study size was arrived at	5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5-6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6-7
		(b) Describe any methods used to examine subgroups and interactions	6-7
		(c) Explain how missing data were addressed	6-7
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	6-7
		(e) Describe any sensitivity analyses	6-7

Continued on next page



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7
		(b) Give reasons for non-participation at each stage	7
		(c) Consider use of a flow diagram	Supplementary material
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	7-8
		(b) Indicate number of participants with missing data for each variable of interest	7-8
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	7
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	8-9
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	7-10
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Supplementary material
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	11
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	13-14
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11-14
Generalisability	21	Discuss the generalisability (external validity) of the study results	14
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	14

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely

1  
2 available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at  
3 <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is  
4 available at [www.strobe-statement.org](http://www.strobe-statement.org).  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only